Efficient HPK1 degradation agent compound as well as preparation method and application thereof
By developing HPK1 degrading agent compounds with specific structural formulas, using targeted protein degradation technology, the problem that existing drugs cannot effectively target HPK1 targets is solved, effectively degrading HPK1 protein and improving immune function, significantly improving HPK1 relatedness The treatment effect of the disease.
Patent Information
- Application Number
- CN202411063964.0
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2023-08-11
- Filing Date
- 2024-08-05
- Publication Date
- 2024-11-22
AI Technical Summary
Existing drugs have not yet been effectively targeted at HPK1 targets, resulting in a gap in clinical demand in tumor immunotherapy, especially in the lack of efficient targeted drugs in improving T cell function and anti-immunosuppressive tumor microenvironment.
A new HPK1 degrader compound has been developed with a specific structural formula (I) that can effectively degrade HPK1 proteins through the mechanism of targeted protein degradation technology (PROTAC) to prevent and treat cancer and immunity associated with HPK1 activity. disease.
This compound can significantly degrade HPK1 protein, improve T cell function, significantly stimulate human PBMC cells to secrete the cytokine interleukin-2, and have a small impact on cell viability, providing a safe and efficient treatment to deal with HPK1-related diseases.
Smart Images

Figure BDA0004978829770000011 
Figure BDA0004978829770000021 
Figure BDA0004978829770000041
Abstract
Description
Technical Field
[0001] The present invention belongs to the field of biomedicine, and specifically relates to a new HPK1 degrader compound, including a pharmaceutical composition thereof, a preparation method thereof, and an application thereof in preventing and / or treating HPK1-related diseases. Background Art
[0002] Targeted protein degradation is one of the emerging directions in the field of drug research and development. As a new drug discovery technology, PROTAC can connect the target protein to the E3 ligase, thereby inducing the ubiquitination of the target protein, enabling the proteasome to recognize and degrade the target protein. Unlike the occupancy-driven mechanism of traditional small molecule inhibitors, the protein degradation mechanism of PROTAC molecules does not require a high degree of binding to the active site of the target protein, and it can maintain its efficacy at lower concentrations and is also more durable.
[0003] Hematopoietic progenitor kinase 1 (HPK1, also known as MAP4K1) is a serine / threonine kinase that is mainly expressed in hematopoietic cells, including their progenitor cells, and is particularly highly expressed in T cells, B cells, and dendritic cells. HPK1 is an important immunosuppressive regulatory kinase, and its function on T cells has been well studied. It inhibits the activity of the T cell receptor (TCR) signaling pathway by phosphorylating the receptor protein SLP76, affecting downstream T cell activation and proliferation. HPK1 can bind to many adaptor proteins, such as the SLP76 family, Gads, HIP-55, GRB2 family, LAT, CRK family, etc., to activate the SAPK / JNK signaling pathway of hematopoietic stem cells, thereby negatively regulating the TCR pathway. Studies have found that HPK1 expression in different cancer patients is positively correlated with T cell exhaustion signals. Inhibition of the HPK1 pathway has potential for application in improving T cell function, antigen presentation, and combating immunosuppressive tumor microenvironment. In addition to the above-mentioned main role of HPK1 through kinase activity, there are also literature reports that it has a scaffold function, and HPK1 gene knockout mice do not have any abnormalities in the resting state. These two points indicate that the development of HPK1 degraders can more completely inhibit HPK1-related functions with good safety.
[0004] Many studies have shown that HPK1 is a potential target for tumor immunotherapy, but there are currently no drugs targeting HPK1 on the market, so more highly effective drugs targeting HPK1 need to be developed to meet clinical needs. Summary of the invention
[0005] The present invention provides a compound having a structure of formula (I), or a stereoisomer, tautomer, solvate, pharmaceutically acceptable salt, metabolite, isotope derivative, N-oxide or prodrug thereof:
[0006]
[0007] in:
[0008] X 1 and X 2 Each independently represents CH, CF or N;
[0009] R 1 represents an optionally substituted phenyl group or an optionally substituted 5-11-membered heteroaryl group;
[0010] R a and R b Each independently represents hydrogen, fluorine, C1-C3 alkyl, C3-C6 cycloalkyl, R a , R b It can form a 3-6 membered ring with the carbon atom to which it is connected, can contain 0-2 heteroatoms selected from N, O, S, and can be a spiro ring or a bridged ring;
[0011] Ring A represents a benzene ring, a 5-9 membered heteroaromatic ring or a 9-10 membered heterocyclic ring;
[0012] R 2 Each independently represents halogen, -R, -(C0-C3)alkylene-cyano, -(C0-C3)alkylene-OR, -(C0-C3)alkylene-NR2, -(C0-C3)alkylene-S(O2)R, -(C0-C3)alkylene-C(O)R, -(C0-C3)alkylene-(C3-C6)cycloalkyl, -(C0-C3)alkylene-4-7 membered heterocycloalkyl, and the alkyl, haloalkyl, cycloalkyl and heterocycloalkyl may be independently and optionally substituted by 0, 1 or 2 of the following substituents: halogen, cyano, -R, -OR, -NR2, -S(O2)R; or two R on adjacent A ring atoms 2 Together with the ring atoms connected to it, it can further form a ring;
[0013] R each independently represents hydrogen, C1-C3 alkyl, C1-C3 haloalkyl;
[0014] ULM is selected from the following structures:
[0015]
[0016] Among them, X 3 , X 4 , X 5 , X 6 and X 8Each independently represents CH, N or CR 3 , where R 3 Each independently represents H, fluorine, chlorine, methyl, methoxy, trifluoromethyl;
[0017] X 7 Each independently represents -CH2- or -C(O)-;
[0018] X 9 each independently represents -NH-, -N(Me)- or -O-;
[0019] X 10 Each independently represents N or CH;
[0020] X 11 Each independently represents -O-, -NH-, -N(Me)-, -CH2- or -C(Me)2-;
[0021] Y each independently represents CH, CD, CMe or N;
[0022] Z each independently represents a bond, -NH-, -O- or -CH2-;
[0023] L means -C1~C 21 Alkylene-, optionally, wherein 0, 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 alkylene groups can be independently replaced by a group selected from the following: -4-12 membered heterocycloalkyl-, -3-12 membered cycloalkyl-, -O-, -NR L -, -C=C-, -C≡C-, -C(O)-, N(R L )-、-C(O)N(R L )-、-N(R L )C(O)-, wherein the heterocycloalkyl or cycloalkyl may be optionally substituted by 0, 1, 2, 3 or 4 of the following substituents: halogen, hydroxy, amino, methyl or oxo (=O), and the R L Each independently represents H, C1-C3 alkyl;
[0024] L may be optionally substituted with 0, 1, 2, 3 or 4 of the following substituents: halogen, C1-C3 alkyl, C3-C6 cycloalkyl, -(C0-C3)alkylene-OR, -(C0-C3)alkylene-NR2, -(C0-C3)alkylene-SR or oxo (=O);
[0025] p represents 0, 1 or 2.
[0026] In one embodiment, X 1 represents CH or N; preferably, X 1 Indicates CH.
[0027] In one embodiment, X 2 represents CH or N; preferably, X 2 Indicates CH.
[0028] In a more preferred embodiment, X 1 Indicates CH, X 2 Indicates CH.
[0029] In one embodiment, R 1 The phenyl or heteroaryl group may be optionally substituted by 0, 1, 2 or 3 substituents selected from the group consisting of hydrogen, halogen, -(C0-C3)alkylene-hydroxy, -(C0-C3)alkylene-amino, -(C0-C3)alkylene-cyano, -(C0-C3)alkylene-(C1-C3)alkyl, -(C0-C3)alkylene-(C1-C3)alkoxy, -(C0-C3)alkylene-(C1-C3)haloalkyl, -(C0-C3)alkylene-(C3-C6)cycloalkyl, and -(C0-C3)alkylene-4-7 membered heterocycloalkyl.
[0030] In a preferred embodiment, R 1 The phenyl or heteroaryl may be optionally substituted by 0, 1, 2 or 3 substituents selected from the group consisting of hydrogen, halogen, hydroxy, amino, cyano, C1-C3 alkyl, C1-C3 alkoxy, C1-C3 haloalkyl, C3-C6 cycloalkyl, 4-7 membered heterocycloalkyl.
[0031] In a more preferred embodiment, R 1 represents a 5-11 membered heteroaryl group, which may be optionally substituted by 0, 1 or 2 of the following substituents: hydrogen, halogen, hydroxy, amino, cyano, methyl, methoxy, fluoromethyl; more preferably, R 1 express More preferably, R 1 express
[0032] In one embodiment, R a and R b Each independently represents hydrogen, fluorine, or methyl; preferably, R a and R b Both represent hydrogen.
[0033] In one embodiment, ring A represents a 5-6 membered heteroaromatic ring or a 9-10 membered heterocyclic ring; preferably, ring A represents a pyridine ring, a pyrimidine ring, a pyrazole ring, or a pyridopiperidine ring; more preferably, A represents a pyridine ring.
[0034] In one embodiment, R 2Each independently represents halogen, cyano, -R, -OR, -NR2, -S(O2)R, -C(O)R, C3-C6 cycloalkyl, 4-7 membered heterocycloalkyl, and the alkyl, haloalkyl, cycloalkyl and heterocycloalkyl may be independently and optionally substituted by 0, 1 or 2 of the following substituents: halogen, cyano, -R, -OR, -NR2, -S(O2)R;
[0035] In a preferred embodiment, R 2 Each independently represents halogen, cyano, -R, -OR, -NR2, C1-C3 alkyl, C3-C6 cycloalkyl, 4-7 membered heterocycloalkyl, and the alkyl, haloalkyl, cycloalkyl and heterocycloalkyl may be independently and optionally substituted by 0, 1 or 2 of the following substituents: halogen, cyano, -R, -OR, -NR2, -S(O2)R; preferably, R each independently represents hydrogen, methyl, trifluoromethyl.
[0036] In one embodiment, p represents 0 or 1.
[0037] In one embodiment, express The end marked with * is connected to the N side of NH of formula (I), and the end marked with ** is connected to the L end of formula (I); preferably, express The end marked with * is connected to the N side of NH of formula (I), and the end marked with ** is connected to the L end of formula (I); more preferably, express The end marked with * is connected to the N side of NH of formula (I), and the end marked with ** is connected to the L end of formula (I).
[0038] In one embodiment, the ULM is selected from the following structures:
[0039]
[0040] Where R 3 Each independently represents H, fluorine, chlorine, methyl, methoxy or trifluoromethyl.
[0041] In a preferred embodiment, the ULM is selected from the following structures:
[0042]
[0043]
[0044] In one embodiment, L represents -C3 to C 18 Alkylene-, more preferably L represents -C3~C 15Alkylene-, optionally, wherein 0, 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 alkylene groups can be independently replaced by a group selected from the following: -4-12 membered heterocycloalkyl-, -3-12 membered cycloalkyl-, -O-, -NR L -, -C=C-, -C≡C-, -C(O)-, N(R L )-、-C(O)N(R L )-、-N(R L )C(O)-, wherein the heterocycloalkyl or cycloalkyl may be optionally substituted by 0, 1, 2, 3 or 4 of the following substituents: halogen, hydroxy, amino, methyl or oxo (=O), and the R L Each independently represents H, C1-C3 alkyl; L may be optionally substituted by 0, 1, 2, 3 or 4 of the following substituents: fluorine, hydroxy, methyl or oxo (=O).
[0045] In a preferred embodiment, L represents -L 1 -L 2 -L 3 -L 4 -L 5 -L 6 – L 1 , L 3 , L 5 Each independently represents a 4- to 12-membered heterocycloalkyl group, a 3- to 12-membered cycloalkyl group, -C(O)-, -N(R L )-、-C(O)N(R L )-、-N(R L )C(O)-, O or a bond, the heterocyclyl or cycloalkyl group may be optionally substituted by 0, 1, 2, 3 or 4 of the following substituents: halogen, hydroxy, amino, methyl or oxo (=O); L 2 , L 4 , L 6 Each independently represents -(OCH2CH2) m -、-(OCH2CH2CH2) m -、-(CH2) n -、-C(O)-、-N(R L )-、-C(O)N(R L )-、-N(R L )C(O)-, -C≡C-, O or a bond; R L They independently represent H, C1-C3 alkyl; m represents 1, 2, 3, 4; n represents 1, 2, 3, 4, 5, 6; L may be optionally substituted by 0, 1, 2, 3 or 4 of the following substituents: fluorine, hydroxyl, methyl or oxo (=O).
[0046] In a more preferred embodiment, L represents -L 1 -L 2 -L 3 -L 4 -L 5 -L 6 – L 1 , L 3 , L 5 Each independently represents a 4- to 12-membered heterocycloalkyl group, a 3- to 12-membered cycloalkyl group, -C(O)-, -N(R L )-, O or a bond, the heterocyclyl or cycloalkyl may each be optionally substituted by 0, 1, 2, 3 or 4 of the following substituents: halogen, hydroxy, amino, methyl or oxo (=O); more preferably, the heterocyclyl or cycloalkyl may each be optionally substituted by 0, 1, 2, 3 or 4 of the following substituents: halogen, methyl; more preferably, the heterocyclyl or cycloalkyl is substituted by 0 substituents.
[0047] In a more preferred embodiment, L represents -L 1 -L 2 -L 3 -L 4 -L 5 -L 6 – L 2 , L 4 , L 6 Each independently represents -(OCH2CH2) m -、-(CH2) n -、-C(O)-、-N(R L )-, -C≡C-, O or a bond; preferably, L 2 , L 4 , L 6 Each independently represents -(CH2) n -、-C(O)-、-N(R L, )-, -C≡C-, O or a bond; m represents 1 or 2; n represents 1, 2, 3, 4, 5 or 6.
[0048] In a preferred embodiment, L is selected from the following structures:
[0049]
[0050]
[0051]
[0052] The present invention covers any combination of the above embodiments.
[0053] More preferably, in some embodiments of the present invention, the compound represented by formula (I) is any of the following compounds:
[0054]
[0055]
[0056]
[0057]
[0058]
[0059]
[0060]
[0061] In another aspect, the present invention also provides a pharmaceutical composition comprising the compound as described above, or its stereoisomers, tautomers, solvates, pharmaceutically acceptable salts, metabolites, isotopic derivatives, N-oxides or prodrugs, and a pharmaceutically acceptable carrier, diluent or excipient.
[0062] In another aspect, the present invention also provides the use of the compound as described above, or its stereoisomers, tautomers, solvates, pharmaceutically acceptable salts, metabolites, isotopic derivatives, N-oxides or prodrugs, or pharmaceutical compositions in drugs for preventing and / or treating diseases associated with HPK1 activity. The HPK1 activity-related diseases include cancer or immune diseases; the cancer is preferably lung cancer, thyroid cancer, liver cancer, colorectal cancer, colon cancer, rectal cancer, pancreatic cancer, gastric cancer, esophageal cancer, squamous cell carcinoma, head and neck cancer, oral cancer, thyroid cancer, nasopharyngeal cancer, breast cancer, ovarian cancer, prostate cancer, cervical cancer, kidney cancer, endometrial cancer, bladder cancer, bone cancer, brain cancer, skin cancer, melanoma, sarcoma, cell tumor, glioma, blood tumor and lymphoma; the immune disease is preferably lupus erythematosus, psoriasis, inflammatory bowel disease and rheumatoid arthritis.
[0063] In one aspect, the present invention also provides a method for preventing and / or treating diseases associated with HPK1 activity, comprising administering a therapeutically effective amount of the compound as described above, or its stereoisomers, tautomers, solvates, pharmaceutically acceptable salts, metabolites, isotopic derivatives, N-oxides or prodrugs, or pharmaceutical compositions to a patient in need thereof. The HPK1 activity-related diseases include cancer or immune diseases; the cancer is preferably lung cancer, thyroid cancer, liver cancer, colorectal cancer, colon cancer, rectal cancer, pancreatic cancer, gastric cancer, esophageal cancer, squamous cell carcinoma, head and neck cancer, oral cancer, thyroid cancer, nasopharyngeal cancer, breast cancer, ovarian cancer, prostate cancer, cervical cancer, kidney cancer, endometrial cancer, bladder cancer, bone cancer, brain cancer, skin cancer, melanoma, sarcoma, cell tumor, glioma, blood tumor and lymphoma; the immune disease is preferably lupus erythematosus, psoriasis, inflammatory bowel disease and rheumatoid arthritis.
[0064] In another aspect, in the above-mentioned uses or methods, the above-mentioned compounds, or their stereoisomers, tautomers, solvates, pharmaceutically acceptable salts, metabolites, isotope derivatives, N-oxides or prodrugs, or pharmaceutical compositions can be used alone or in combination with other types of pharmaceutical preparations and / or treatment methods.
[0065] It is specifically noted that, herein, when referring to a "compound" having a specific structural formula, stereoisomers, diastereomers, enantiomers, racemic mixtures and isotopic derivatives thereof are generally also encompassed.
[0066] It is well known to those skilled in the art that a salt, solvate, or hydrate of a compound is an alternative form of the compound, and they can all be converted into the compound under certain conditions. Therefore, it should be noted that when a compound is mentioned in this article, it generally also includes its pharmaceutically acceptable salts, and further includes its solvates and hydrates.
[0067] Similarly, when a compound is referred to herein, prodrugs, metabolites, and N-oxides thereof are also generally included.
[0068] The "stereoisomer" of the compound of formula (I) of the present invention means that when the compound of formula (I) has an asymmetric carbon atom, enantiomers will be produced; when the compound has a carbon-carbon double bond or a cyclic structure, cis-trans isomers will be produced; when the compound has a ketone or oxime, etc., it will produce tautomers. All enantiomers, diastereomers, racemates, cis-trans isomers, tautomers, geometric isomers, diastereomers and mixtures thereof of the compound of formula (I) are included in the scope of the present invention.
[0069] The "pharmaceutically acceptable salt" of the present invention refers to a pharmaceutically acceptable acid and base addition salt or a solvate thereof. Such pharmaceutically acceptable salts include salts of the following acids: hydrochloric acid, phosphoric acid, hydrobromic acid, sulfuric acid, sulfurous acid, formic acid, toluenesulfonic acid, methanesulfonic acid, nitric acid, benzoic acid, citric acid, tartaric acid, maleic acid, hydroiodic acid, alkanoic acid (such as acetic acid, HOOC-(CH2)n-COOH (wherein n is 0 to 4)), etc. Alkaline salts: sodium salts, potassium salts, calcium salts, ammonium salts, etc. A variety of non-toxic pharmaceutically acceptable addition salts known to those skilled in the art.
[0070] The pharmaceutically acceptable salts of the present invention can be prepared by conventional methods, for example, by dissolving the compound of the present invention in a water-miscible organic solvent (e.g., acetone, methanol, ethanol and acetonitrile), adding an excess of an organic acid or an aqueous inorganic acid solution thereto to precipitate the salt from the resulting mixture, removing the solvent and the remaining free acid therefrom, and then isolating the precipitated salt.
[0071] The precursors or metabolites of the present invention may be precursors or metabolites known in the art, as long as the precursors or metabolites are converted to compounds by in vivo metabolism. For example, "prodrugs" refer to those prodrugs of the compounds of the present invention, which are suitable for contact with human and lower animal tissues within the scope of reasonable medical judgment, without undue toxicity, irritation, allergic reactions, etc., and are considered to have a reasonable benefit / risk ratio and are effective for their intended use. The term "prodrug" refers to a compound that is rapidly converted in vivo to produce the parent compound of the above formula, for example, by metabolism in vivo.
[0072] The present invention provides a compound of a specific formula (I) and its pharmaceutically acceptable salts, solvates, stereoisomers, prodrugs and metabolites for use in preventing and / or treating HPK1-related diseases.
[0073] The HPK1-related diseases described in the present invention include cancer, inflammation, immune diseases and the like.
[0074] The compounds of the present invention described in the present invention can be used alone or in combination with other types of pharmaceutical preparations (such as PD-1 / PD-L1 antagonists, etc.) and / or treatment methods (such as radiotherapy / chemotherapy, etc.) in the prevention and / or treatment of HPK1-related diseases.
[0075] The present invention also provides use of the compound of the present invention in preparing a medicament for preventing and / or treating HPK1-related cancers, inflammation and immune diseases.
[0076] In addition, the present invention provides a pharmaceutical composition for preventing and / or treating HPK1-related cancers, inflammation and immune diseases, which comprises the compound of the present invention as an active ingredient. DETAILED DESCRIPTION OF THE INVENTION
[0078] definition
[0079] Unless otherwise specified, the terms used in the present application (including the specification and claims) are defined as follows. It must be noted that in the specification and the appended claims, the singular form "a" includes the plural meaning unless otherwise clearly indicated in the text. If not otherwise specified, conventional methods of mass spectrometry, nuclear magnetic resonance, HPLC, protein chemistry, biochemistry, recombinant DNA technology and pharmacology are used. In this application, if not otherwise specified, the use of "or" or "and" means "and / or".
[0080] In the specification and claims, a given chemical formula or name shall encompass all stereo and optical isomers and racemates in which such isomers are present. Unless otherwise indicated, all chiral (enantiomers and diastereomers) and racemic forms are within the scope of the present invention. Many geometric isomers of C=C double bonds, C=N double bonds, ring systems, etc. may also be present in the compounds, and all such stable isomers are encompassed by the present invention. The present invention describes cis- and trans- (or E- and Z-) geometric isomers of the compounds of the present invention, and they can be separated into mixtures of isomers or separated isomeric forms. The compounds of the present invention can be separated in optically active or racemic form. All methods for preparing the compounds of the present invention and the intermediates prepared therein are considered to be part of the present invention. When enantiomeric or diastereomeric products are prepared, they can be separated by conventional methods (e.g., by chromatography or fractional crystallization). Depending on the process conditions, the final products of the present invention are obtained in free (neutral) or salt form. Both the free form and the salts of these final products are within the scope of the present invention. If desired, one form of the compound may be converted into another form. A free base or acid may be converted into a salt; a salt may be converted into a free compound or another salt; a mixture of isomeric compounds of the invention may be separated into individual isomers. The compounds of the invention, their free forms and salts may exist in a variety of tautomeric forms, in which hydrogen atoms are transposed to other parts of the molecule and the chemical bonds between the atoms of the molecule are thereby rearranged. It should be understood that all tautomeric forms that may exist are included in the present invention.
[0081] In the present invention, when the listed linking groups do not specify their connection direction, their connection direction is arbitrary, for example L is -C(O)NH-, in which case -C(O)NH- can be connected to phenyl and cyclohexyl in the order of reading from left to right to form It is also possible to connect phenyl and cyclohexyl groups in the reverse reading order from left to right to form Combinations of linking groups and linked groups are permissible only if such combinations result in stable compounds.
[0082] Unless otherwise defined, the definitions of substituents in the present invention are independent of each other and not related to each other. For example, for a substituent R a (or R b ), they are independent of each other in the definitions of different substituents. Specifically, for R a (or R b ) When a definition is selected for a substituent, it does not mean that R a (or R b ) has the same definition in other substituents. More specifically, for example (only non-exhaustive) for NR a R b In the case of R a (or R b ) is selected from hydrogen, it does not mean that in -C(O)-NR a R b In, R a (or R b ) is necessarily hydrogen. In another aspect, when more than one R is present in a substituent a (or R b ),these R a (or R b ) are also independent of each other. For example, in the substituent -(CR a R b ) m -O-(CR a R b ) n -, when m+n is greater than or equal to 2, the m+n R a (or R b ) are independent of each other and can have the same or different meanings.
[0083] Unless otherwise defined, when a substituent is noted as "optionally substituted", the substituent is selected, for example, from substituents such as alkyl, cycloalkyl, aryl, heterocyclyl, halogen, hydroxy, alkoxy, oxo, alkanoyl, aryloxy, alkanoyloxy, amino, alkylamino, arylamino, arylalkylamino, disubstituted amine groups (wherein the two amino substituents are selected from alkyl, aryl or arylalkyl), alkanoylamino, aroylamino, aralkanoylamino, substituted alkanoylamino, substituted arylamino, substituted aralkanoylamino, thio, alkylthio, arylthio, arylalkylthio, arylthiocarbonyl, arylalkylthiocarbonyl , alkylsulfonyl, arylsulfonyl, arylalkylsulfonyl, sulfonylamino such as -SO2NH2, substituted sulfonylamino, nitro, cyano, carboxyl, carbamoyl such as -CONH2, substituted carbamoyl such as -CONHalkyl, -CONHRyl, -CONHRylalkyl or in the case of having two substituents on nitrogen selected from alkyl, aryl or arylalkyl, alkoxycarbonyl, aryl, substituted aryl, guanidinyl, heterocyclic groups such as indolyl, imidazolyl, furanyl, thienyl, thiazolyl, pyrrolidinyl, pyridinyl, pyrimidinyl, pyrrolidinyl, piperidinyl, morpholinyl, piperazinyl, homopiperazinyl and the like and substituted heterocyclic groups.
[0084] In the present invention, the term "alkyl" is intended to include branched and straight chain saturated aliphatic hydrocarbon groups with a specified number of carbon atoms. For example, "C1-C6 alkyl" represents an alkyl group with 1 to 6 carbon atoms. Examples of alkyl groups include, but are not limited to, methyl (Me), ethyl (Et), n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl, n-pentyl, isopentyl, neopentyl. Alkyl can be non-substituted or substituted, and when substituted, it can be substituted at any usable point of attachment, and the substituent is preferably one or more of deuterium, halogen, hydroxyl, amino, cyano, alkyl, alkoxy, haloalkyl, cycloalkyl, heterocycloalkyl, aryl and heteroaryl. Preferred alkyl groups of the present invention include C1-C6 alkyl or C1-C4 alkyl.
[0085] In the present invention, the term "alkylene" is intended to include a saturated aliphatic hydrocarbon group having a specified number of carbon atoms, a straight chain, a cyclic alkyl group or a cyclic alkyl group, which is a residue derived from the same carbon atom or two different carbon atoms of the parent alkane by removing two hydrogen atoms. For example, "C0-C6 alkylene" means an alkylene group having 0 to 6 carbon atoms, and C0 alkylene means that the alkylene group does not exist (a bond). Examples of alkylene groups include, but are not limited to, methylene (-CH2-), 1,1-ethylene (-CH(CH3)-), 1,2-ethylene (-CH2CH2-), 1,1-propylene (-CH(CH2CH3)-), 1,2-propylene (-CH2CH(CH3)-), 1,3-propylene (-CH2CH2CH2-), 1,4-butylene (-CH2CH2CH2CH2-), etc. In this context, the alkylene group is preferably an alkylene group having 0-6, 0-4, 0-3, 1-6, 1-4, 1-3 carbon atoms. In this context, the alkylene group is preferably an alkylene group not containing a cyclic alkyl group.
[0086] In the present invention, the term "cycloalkyl" refers to a monocyclic, polycyclic or branched cyclic alkyl group. 12 Cyclic alkyl includes but is not limited to cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl and norbornyl. Branched cycloalkyls such as 1-methylcyclopropyl and 2-methylcyclopropyl are included in the definition of "cycloalkyl". Polycyclic, for example bicyclic and tricyclic cycloalkyls include cycloalkyls of bridged rings, spiro rings or condensed rings. Cyclic alkyls can be unsubstituted or substituted, and when substituted, they can be substituted at any usable point of attachment, and the substituents are preferably selected from one or more of halogen, hydroxyl, amino, cyano, oxo, alkyl, alkoxy, haloalkyl, cycloalkyl, heterocycloalkyl, aryl and heteroaryl. In the present invention, cycloalkyl is preferably C3-C 12 Cycloalkyl, more preferably C3-C8 cycloalkyl.
[0087] In the present invention, the term "3-12 membered cycloalkyl" refers to a saturated or partially unsaturated monocyclic or polycyclic alkyl system consisting of 3 to 12 ring atoms, and the ring atoms are all carbon atoms. It includes monocyclic alkyl, cycloalkyl, spirocyclic alkyl and bridged cycloalkyl. The "3-12 membered cycloalkyl" can be a 3, 4, 5, 6, 7, 8, 9, 10, 11 or 12 membered cycloalkyl. Specific examples of 3-12 membered heterocyclic groups include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclopentylcyclopentyl, cyclobutylspirocyclobutyl or wait.
[0088] In the present invention, the term "heterocycloalkyl" refers to a cyclic structure in which at least one carbon atom on the cycloalkyl ring structure is replaced by a heteroatom selected from N, O, S and P. Wherein the N atom may be optionally quaternized, and the N and S atoms may be optionally oxidized (i.e., NO, SO and SO2). It includes monocyclic heterocyclic, bicyclic heterocyclic and tricyclic heterocyclic systems, wherein the bicyclic heterocyclic and tricyclic heterocyclic systems include spirocyclic heterocyclic, cyclic heterocyclic and bridged heterocyclic. Heterocycloalkyl may be unsubstituted or substituted, and when substituted, it may be substituted at any usable connection point, and the substituent is preferably selected from one or more of halogen, hydroxyl, amino, cyano, oxo, alkyl, alkoxy, haloalkyl, cycloalkyl, heterocycloalkyl, aryl and heteroaryl. In the present invention, heterocycloalkyl is preferably 4-12 membered heterocycloalkyl, more preferably 4-8 membered heterocycloalkyl.
[0089] In the present invention, the term "4-12 membered heterocycloalkyl" or "4-12 membered heterocyclic group" refers to a saturated or partially unsaturated monocyclic or polycyclic heterocyclic alkyl system consisting of 4 to 12 ring atoms, wherein 1, 2, 3 or 4 ring atoms are heteroatoms independently selected from N, O and S, and the rest are carbon atoms, wherein the N atom may be optionally quaternized, and the N and S atoms may be optionally oxidized (i.e., NO, SO and SO2). When the total number of S and O atoms in the heterocycle exceeds 1, these heteroatoms are not adjacent to each other. It includes monocyclic heterocycles, bicyclic heterocycles and tricyclic heterocycle systems, wherein the bicyclic heterocycles and tricyclic heterocycle systems include spirocyclic heterocycles, cyclic heterocycles and bridged heterocycles. The "4-12 membered heterocyclic group" may be a 4, 5, 6, 7, 8, 9, 10, 11 or 12 membered heterocyclic group. Specific examples of 4-12 membered heterocyclic groups include, but are not limited to, azetidinyl, oxetanyl, pyrrolidinyl (including 2-pyrrolidinyl and 3-pyrrolidinyl), piperidinyl (including 2-piperidinyl, 3-piperidinyl and 4-piperidinyl, etc.), piperazinyl, hexahydropyridazinyl, morpholinyl, dioxanyl, hexahydropyridazinyl, azepanyl, 1,4-diazepanyl, cyclopentylpyrrolidinyl, pyrrolidinylpyrrolidinyl, cyclopropylspiropiperazinyl, cyclobutylspiroazetidinyl, azetidinylspiroazetidinyl, cyclobutylspiroazacyclopentyl, azetidinylspirocyclopentyl, azetidinylspiroazacyclopentyl, cyclobutylspiroazacyclohexyl, azetidinylspirocyclohexyl, azetidinylspiroazacyclohexyl, cyclopentylspiroazacyclopentyl, azocyclopentylspiroazacyclopentyl, wait.
[0090] In the present invention, the term "paracyclic" refers to a polycyclic group formed by two or more cyclic structures sharing two adjacent atoms.
[0091] In the present invention, the term "bridged ring" refers to a polycyclic group in which two rings in the system share two or more ring atoms.
[0092] In the present invention, the term "spirocycle" refers to a polycyclic group in which single rings share a carbon atom (called a spiro atom).
[0093] In the present invention, the term "alkenyl" refers to a straight or branched hydrocarbon group containing one or more double bonds and generally having a length of 2 to 20 carbon atoms. For example, a "C2-C6 alkenyl" contains two to six carbon atoms. Alkenyl includes, but is not limited to, for example, vinyl, propenyl, butenyl, 1-methyl-2-butene-1-yl, etc. Preferred alkenyl groups of the present invention include C2-C6 alkenyl.
[0094] The term "cycloalkenyl" refers to a monocyclic or bicyclic cyclic alkenyl. Monocyclic cyclic alkenyl refers to a C3-C8 cyclic alkenyl, including but not limited to cyclopropenyl, cyclobutenyl, cyclopentenyl, cyclohexenyl and norbornyl. Branched cycloalkenyls such as 1-methylcyclopropenyl and 2-methylcyclopropenyl are included in the definition of "cycloalkenyl". Bicyclic cyclic alkenyls include cyclic alkenyls of bridged rings, spiro rings or condensed rings.
[0095] In the present invention, the term "alkynyl" refers to a straight or branched hydrocarbon group containing one or more triple bonds and generally having a length of 2 to 20 carbon atoms. For example, a "C2-C6 alkynyl" contains two to six carbon atoms. Representative alkynyl groups include, but are not limited to, ethynyl, 1-propynyl, 1-butynyl, etc. Preferred alkynyl groups of the present invention include C2-C6 alkynyl.
[0096] In the present invention, the term "alkoxy" or "alkyloxy" refers to -O-alkyl. "C1-C6 alkoxy" (or alkyloxy) is intended to include C1, C2, C3, C4, C5, C6 alkoxy. Examples of alkoxy include, but are not limited to, methoxy, ethoxy, propoxy (e.g., n-propoxy and isopropoxy) and tert-butoxy. Similarly, "alkylthio" or "thioalkoxy" represents an alkyl group as defined above connected via a sulfur bridge with a specified number of carbon atoms; for example, methyl-S- and ethyl-S-. Preferred alkoxy groups of the present invention include C1-C6 alkoxy or C1-C4 alkoxy. Alkoxy can be unsubstituted or substituted, and when substituted, it can be substituted at any usable point of attachment, and the substituent is preferably one or more of deuterium, halogen, hydroxyl, amino, cyano, alkyl, alkoxy, haloalkyl, cycloalkyl, heterocycloalkyl, aryl and heteroaryl.
[0097] In the present invention, the term "carbonyl group" refers to an organic functional group (C=O) formed by connecting carbon and oxygen atoms through a double bond.
[0098] In the present invention, the term "aryl", alone or as part of a larger moiety such as "aralkyl", "aralkyloxy" or "aryloxyalkyl", refers to a monocyclic, bicyclic or tricyclic ring system having a total of 5 to 12 ring members, wherein at least one ring in the system is aromatic and wherein each ring in the system contains 3 to 7 ring members. In certain embodiments of the present invention, "aryl" refers to an aromatic ring system, which includes but is not limited to phenyl, biphenyl, indanyl, 1-naphthyl, 2-naphthyl and tetrahydronaphthyl. The term "aralkyl" or "arylalkyl" refers to an alkyl residue attached to an aryl ring. Non-limiting examples include benzyl, phenethyl, etc. The fused aryl group may be attached to another group at a suitable position on the cycloalkyl ring or the aromatic ring. The dotted line drawn from the ring system indicates that the bond may be attached to any suitable ring atom. The aryl group may be unsubstituted or substituted, and when substituted, it may be substituted at any available point of attachment, and the substituents are preferably selected from one or more of deuterium, halogen, hydroxy, amino, cyano, alkyl, alkoxy, haloalkyl, cycloalkyl, heterocycloalkyl, aryl and heteroaryl.
[0099] In the present invention, the term "heteroaryl" means a stable 5-, 6-, or 7-membered aromatic monocyclic or aromatic bicyclic or 7-, 8-, 9-, 10-, 11-, or 12-membered aromatic polycyclic heterocyclic ring, which is completely unsaturated or partially unsaturated, and contains carbon atoms and 1, 2, 3, or 4 heteroatoms independently selected from N, O, and S; it includes a structure in which a cycloalkane or heterocycloalkane is fused with an aromatic ring such as a benzene ring or a heteroaromatic ring such as pyridine, and the structure can be located on a cycloalkane, heterocycloalkane, aromatic ring, or heteroaromatic ring as a substituent. Nitrogen and sulfur heteroatoms may be optionally oxidized. The nitrogen atom is substituted or unsubstituted (i.e., N or NR, wherein R is H or, if defined, another substituent). The heterocycle may be connected to its side group at any heteroatom or carbon atom to obtain a stable structure. If the resulting compound is stable, the heterocyclic group described herein may be substituted on a carbon or nitrogen atom. The nitrogen in the heterocycle may be optionally quaternized. Preferably, when the total number of S and O atoms in the heterocycle exceeds 1, these heteroatoms are not adjacent to each other. Preferably, the total number of S and O atoms in the heterocycle is not greater than 1. The heteroaryl group may be unsubstituted or substituted, and when substituted, it may be substituted at any available point of attachment, the substituent preferably being one or more selected from halogen, hydroxyl, amino, cyano, alkyl, alkoxy, haloalkyl, cycloalkyl, heterocycloalkyl, aryl and heteroaryl. When the term "heterocycle" is used, it is intended to include heteroaryl. The term "heteroaryl" may also include biaryl structures formed by the above-defined "aryl" and the monocyclic "heteroaryl", such as but not limited to "-phenyl bipyridyl-", "-phenyl bipyrimidyl", "-pyridyl biphenyl", "-pyridyl bipyrimidyl-", "-pyrimidyl biphenyl-"; wherein the present invention also includes fused ring and spiro compounds containing, for example, the above-mentioned heterocycles.
[0100] In the present invention, the term "substituted" means that at least one hydrogen atom is replaced by a non-hydrogen group, provided that normal valence is maintained and the substitution results in a stable compound. The ring double bond used herein is a double bond formed between two adjacent ring atoms (e.g., C=C, C=N or N=N).
[0101] In the present invention, one or more halogens may be independently selected from fluorine, chlorine, bromine and iodine.
[0102] In the present invention, the term "halo" or "halogen" includes fluorine, chlorine, bromine and iodine. "Haloalkyl" is intended to include branched and straight-chain saturated aliphatic hydrocarbon groups with a specified number of carbon atoms and substituted with one or more halogens. Examples of haloalkyl include, but are not limited to, fluoromethyl, difluoromethyl, trifluoromethyl, trichloromethyl, pentafluoroethyl, pentachloroethyl, 2,2,2-trifluoroethyl, heptafluoropropyl and heptachloropropyl. Examples of haloalkyl also include "fluoroalkyl" that is intended to include branched and straight-chain saturated aliphatic hydrocarbon groups with a specified number of carbon atoms and substituted with one or more fluorine atoms. "Halocycloalkyl" / "halogenated heterocycloalkyl" is intended to include cycloalkyl / heterocycloalkyl with a specified number of carbon atoms and substituted with one or more halogens. In the present invention, the halogen atom is preferably fluorine or chlorine, more preferably fluorine.
[0103] In the present invention, the term "haloalkoxy" or "haloalkyloxy" means a haloalkyl group as defined above connected via an oxygen bridge with a specified number of carbon atoms. For example, "C1-C6 haloalkoxy" is intended to include C1, C2, C3, C4, C5, C6 haloalkoxy. Examples of haloalkoxy include, but are not limited to, trifluoromethoxy, 2,2,2-trifluoroethoxy, and pentafluoroethoxy. Similarly, "haloalkylthio" or "thiohaloalkoxy" means a haloalkyl group as defined above connected via a sulfur bridge with a specified number of carbon atoms; for example, trifluoromethyl-S- and pentafluoroethyl-S-.
[0104] In the present invention, when referring to some substituent groups, C x1 -C x2 This means that the number of carbon atoms in the substituent group can be x1 to x2 For example, C 0-C8 means that the group contains 0, 1, 2, 3, 4, 5, 6, 7 or 8 carbon atoms, C1-C8 means that the group contains 1, 2, 3, 4, 5, 6, 7 or 8 carbon atoms, C2-C8 means that the group contains 2, 3, 4, 5, 6, 7 or 8 carbon atoms, C3-C8 means that the group contains 3, 4, 5, 6, 7 or 8 carbon atoms, C4-C8 means that the group contains 4, 5, 6, 7 or 8 carbon atoms, C0-C6 means that the group contains 0, 1, 2, 3, 4, 5 or 6 carbon atoms, C1-C6 means that the group contains 1, 2, 3, 4, 5 or 6 carbon atoms, C2-C6 means that the group contains 2, 3, 4, 5 or 6 carbon atoms, and C3-C6 means that the group contains 3, 4, 5 or 6 carbon atoms.
[0105] In the present invention, when referring to a cyclic group (such as an aryl group, a heteroaryl group, a cycloalkyl group and a heterocycloalkyl group), the expression "x1-x2-membered ring" is used, which means that the number of ring atoms of the group can be x1 to x2. For example, the 3-12-membered cyclic group can be a 3-, 4-, 5-, 6-, 7-, 8-, 9-, 10-, 11- or 12-membered ring, and the number of ring atoms thereof can be 3, 4, 5, 6, 7, 8, 9, 10, 11 or 12; a 3-6-membered ring means that the cyclic group can be a 3-, 4-, 5- or 6-membered ring, and the number of ring atoms thereof can be 3, 4, 5 or 6; a 3-8-membered ring means that the cyclic group can be a 3-, 4-, 5-, 6-, 7- or 8-membered ring, and the number of ring atoms thereof can be 3, 4, 5, 6, 7 or 8; a 3-9-membered ring means that the cyclic group can be a 3-, 4-, 5-, 6-, 7-, 8- or 9-membered ring, and the number of ring atoms thereof can be 3, 4, 5, 6, 7, 8 or 9; 4-7 membered ring means that the cyclic group can be a 4, 5, 6 or 7 membered ring, and the number of its ring atoms can be 4, 5, 6 or 7; 5-8 membered ring means that the cyclic group can be a 5, 6, 7 or 8 membered ring, and the number of its ring atoms can be 5, 6, 7 or 8; 5-12 membered ring means that the cyclic group can be a 5, 6, 7, 8, 9, 10, 11 or 12 membered ring, and the number of its ring atoms can be 5, 6, 7, 8, 9, 10, 11 or 12; 6-12 membered ring means that the cyclic group can be a 6, 7, 8, 9, 10, 11 or 12 membered ring, and the number of its ring atoms can be 6, 7, 8, 9, 10, 11 or 12. The ring atoms can be carbon atoms or heteroatoms, such as heteroatoms selected from N, O and S. When the ring is a heterocyclic ring, the heterocyclic ring may contain 1, 2, 3 or 4 ring heteroatoms, for example heteroatoms selected from N, O and S.
[0106] In the case of nitrogen atoms (e.g., amines) present on the compounds of the invention, these nitrogen atoms can be converted to N-oxides by treatment with an oxidizing agent (e.g., mCPBA and / or hydrogen peroxide) to obtain other compounds of the invention. Thus, the nitrogen atoms shown and claimed are considered to encompass both the shown nitrogen and its N-oxide to obtain the derivatives of the invention.
[0107] When any variable occurs more than one time in any constituent or formula for a compound, its definition at each occurrence is independent of its definition at every other occurrence. Thus, for example, if a group is shown substituted with 0-3 R, then the group may be optionally substituted with up to three R groups, and at each occurrence R is independently selected from the definition of R. Furthermore, combinations of substituents and / or variables are permissible only if such combinations result in stable compounds.
[0108] In the present invention, the term "patient" refers to an organism treated by the method of the present invention. Such organisms preferably include but are not limited to mammals (e.g., mice, apes / monkeys, horses, cattle, pigs, dogs, cats, etc.) and most preferably refer to humans.
[0109] In the present invention, the term "effective amount" means the amount of a drug or medicament (i.e., the compound of the present invention) that will cause a biological or medical response of a tissue, system, animal or human being sought by, for example, a researcher or clinician. In addition, the term "therapeutically effective amount" means an amount that results in improved treatment, cure, prevention or alleviation of a disease, condition or side effect, or reduces the rate of progression of a disease or condition, compared to a corresponding subject that has not received the above amount. An effective amount can be administered in one or more administrations, applications or dosages and is not intended to be limited by a specific formulation or route of administration. The term also includes an effective amount that enhances normal physiological function within its scope.
[0110] In the present invention, the term "treatment" includes its broad meaning, covering therapeutic treatment and / or preventive treatment of a subject. Specifically, the "treatment" includes any treatment that leads to the alleviation, inhibition, elimination and improvement and / or prevention of symptoms, diseases, disorders, etc., such as alleviating, reducing, regulating, improving, eliminating, preventing, preventing or improving its symptoms. The therapeutic treatment includes alleviating, inhibiting or improving the symptoms or conditions of the disease; inhibiting the occurrence of complications; improving potential metabolic syndrome; inhibiting the occurrence of diseases or symptoms, such as controlling the development of diseases or conditions; alleviating diseases or symptoms; reducing diseases or symptoms; alleviating complications caused by diseases or symptoms, or treating signs caused by diseases or symptoms. The preventive treatment includes prior treatment to prevent, block or delay, slow down the occurrence or development of diseases or conditions or reduce the severity of diseases or conditions.
[0111] Likewise, "therapeutic agent" also includes agents or reagents that have therapeutic and / or prophylactic effects on a subject.
[0112] In the present invention, the term "pharmaceutical" or "pharmaceutically acceptable" is used herein to refer to those compounds, substances, compositions and / or dosage forms that are suitable for use in contact with human and animal tissues without excessive toxicity, irritation, allergic reaction and / or other problems or complications, and are commensurate with a reasonable benefit / risk ratio, within the scope of reasonable medical judgment.
[0113] In the present invention, the term "pharmaceutically acceptable carrier" or "pharmaceutical carrier" means a pharmaceutical substance, composition or vehicle, such as a liquid or solid filler, diluent, excipient, manufacturing aid (e.g., lubricant, talc, magnesium stearate, calcium stearate or zinc stearate or stearic acid) or solvent encapsulating material, which is involved in carrying or transporting the subject compound from one organ or part of the body to another. Each carrier must be "acceptable" in the sense of being compatible with the other ingredients of the formulation and not harmful to the patient.
[0114] In the present invention, the term "pharmaceutical composition" means a composition comprising a compound of the present invention and at least one other pharmaceutical carrier. "Pharmaceutical carrier" refers to a medium generally accepted in the art for delivering a biologically active agent to an animal (particularly a mammal), including (i.e.) adjuvants, excipients or vehicles, such as diluents, preservatives, fillers, flow regulators, disintegrants, wetting agents, emulsifiers, suspending agents, sweeteners, flavoring agents, aromatics, antibacterial agents, antifungal agents, lubricants and dispersants, depending on the nature of the mode of administration and dosage form.
[0115] Specific pharmaceutical and medical terms
[0116] As used herein, the term "acceptable" means that a formulation component or active ingredient has no undue adverse effect on health and well-being for the general purpose of treatment.
[0117] In the present invention, the term "cancer", as used herein, refers to an abnormal growth of cells that cannot be controlled and can metastasize (spread) under certain conditions. This type of cancer includes, but is not limited to, solid tumors (such as bladder, intestine, brain, chest, uterus, heart, kidney, lung, lymphoid tissue (lymphoma), ovary, pancreas or other endocrine organs (such as thyroid), prostate, skin (melanoma) or blood tumors (such as non-leukemic leukemia).
[0118] In the present invention, the term "combination administration" or similar terms, as used herein, refers to administering several selected therapeutic drugs to one patient in the same or different administration methods at the same or different times.
[0119] In the present invention, the term "enhance" or "can enhance", as used herein, means that the expected result can be increased or prolonged in terms of potency or duration. Therefore, in terms of enhancing the therapeutic effect of a drug, the term "can enhance" refers to the ability of a drug to increase or prolong the potency or duration in a system. The "potency value" used herein refers to the ability to maximize the enhancement of another therapeutic drug in an ideal system.
[0120] In the present invention, the term "immune disease" refers to a disease or symptom caused by an adverse or harmful reaction to an endogenous or exogenous antigen, which usually results in cellular dysfunction, or damage and malfunction, or destruction of organs or tissues that may produce immune symptoms.
[0121] In the present invention, the terms "kit" and "product package" are synonymous.
[0122] In the present invention, the term "subject", "subject" or "patient" includes mammals and non-mammals. Mammals include, but are not limited to, mammals: humans, non-human primates such as gorillas, apes and monkeys; agricultural animals such as cattle, horses, goats, sheep, pigs; livestock such as rabbits and dogs; experimental animals include rodents such as rats, mice and guinea pigs. Non-mammalian animals include, but are not limited to, birds, fish, etc. In a preferred embodiment, the selected mammal is a human.
[0123] As used herein, a compound or pharmaceutical composition, after administration, can improve a disease, symptom or condition, especially improve its severity, delay the onset, slow the progression of the disease, or reduce the duration of the disease. Whether fixed or temporary administration, continuous or intermittent administration, can be attributed to or related to the administration. Specific embodiments
[0124] The present invention can be better understood with reference to the following specific examples, which are intended to illustrate rather than limit the present invention.
[0125] When the preparation route is not mentioned in the present invention, the relevant raw materials and intermediates are purchased from commercial reagents (for example, from Bidex, Yao Shi, etc.).
[0126] The abbreviations in the present invention have the following meanings:
[0127]
[0128] In the following examples, unless otherwise specified, the reaction temperature is room temperature (15-35°C).
[0129] The compounds of the present invention are separated and purified by preparative TLC, silica gel column chromatography, Prep-HPLC and / or flash column chromatography. 1The reaction was confirmed by H NMR and / or MS. The reaction was monitored by TLC or LC-MS.
[0130] 1 H-NMR spectra were recorded at 500 MHz on a Bruker instrument. Chemical shift values are expressed in parts per million, i.e., δ values. The following abbreviations are used for the multiplicity of NMR signals: s = singlet, brs = broad, d = doublet, t = triplet, m = multiplet. Coupling constants are listed as J values, measured in Hz. LC-MS experimental conditions were: Instrument: Thermo U3000, ALLtech ELSD, MSQ, UV detector combined with ELSD and MSD (elution ratio of 4:1). Column: Waters X-Bridge C-18, 3.5 μm, 4.6x50 mm; Column temperature: 30°C. Gradient [time (min) / solvent B in A (%)]: 0.00 / 5.0, 1.40 / 95, 2.80 / 95, 2.82 / 5, 3.00 / 5. (Solvent A = 0.01% trifluoroacetic acid in water; Solvent B = 0.01% trifluoroacetic acid in acetonitrile) UV detection: 214 / 254 / 280 / 300 nm; DAD detection: 210-350 nm; Flow rate: 2 mL / min; MS: ESI, 100-1500 m / z.
[0131] Preparative HPLC used an alkaline method or an acidic method (alkaline method mobile phase: acetonitrile / 0.05% ammonium bicarbonate aqueous solution, acidic method mobile phase: acetonitrile / 0.05% formic acid aqueous solution or acetonitrile / 0.05% TFA aqueous solution); the instrument was ThermoU3000 AFC-3000; column: Globalsil C-18 12 nm, 250 x 20 mm, 10 μm, or equivalent; flow rate: 20 mL / min, for gradient elution separation.
[0132] Synthesis of intermediates
[0133]
[0134] Step 1: Dissolve compound WH-1 (25 g, 149 mmol) in concentrated sulfuric acid (150 mL), add concentrated nitric acid (10 mL, 149 mmol) dropwise at -10 ° C, stir the system at -10 ° C for 2 hours, then warm to room temperature and continue stirring for 2 hours. Pour the reaction solution into ice water (200 mL), precipitate solid, collect by filtration, wash twice with water (50 mL), and then dry to obtain product WH-2 (30 g, yield 95%). ESI-MS (m / z): 213.3 [M+H] + .
[0135] Step 2: Dissolve compound WH-2 (30 g, 141 mmol) in ethanol (300 mL) and water (60 mL), then add iron powder (39.4 g, 705 mmol) and ammonium chloride (45.3 g, 846.7 mmol), and stir the system under reflux for 2 hours. Filter the reaction solution through diatomaceous earth, evaporate the filtrate to remove ethanol, and precipitate. Collect the precipitate by filtration, wash twice with water (50 mL), and then dry to obtain compound WH-3 (24 g, yield 93%). ESI-MS (m / z): 183.5 [M+H] + .
[0136] Step 3: At 0°C, compound WH-3 (24 g, 131 mmol) was added to an aqueous solution of hydrobromic acid (120 mL), and then an aqueous solution of sodium nitrite (18 g, 263 mmol) (120 mL) was added dropwise. The system was stirred at 0°C for 1 hour, and then copper bromide (32.3 g, 144.6 mmol) was added. The system was heated to 80°C and stirred for 2 hours. The reaction solution was poured into ice water, and a solid precipitate was precipitated. It was collected by filtration, washed twice with water (50 mL), and then dried to obtain the product WH-4 (25 g, yield 77%). ESI-MS (m / z): 248.3 [M+H] + .
[0137] Step 4: Add 4-dimethylaminopyridine (14.3 g, 116.8 mmol) and di-tert-butyl dicarbonate (31.8 g, 146.05 mmol) to a solution of compound WH-4 (24 g, 97.4 mol) in tetrahydrofuran (200 mL) at 0°C, and react the system at room temperature for 16 hours. The reaction solution was diluted with ethyl acetate (500 mL), and the organic phase was washed with water and saturated sodium chloride solution. The filtrate was concentrated, and the residue was purified by silica gel column chromatography (petroleum ether / ethyl acetate) to obtain compound WH-5 (29 g, yield 86%). ESI-MS (m / z): 348.2 [M+H] + .
[0138] Step 5: Pd2(dba)3 (2.1 g, 2.3 mmol), Xantphos (1.6 g, 2.8 mmol) and cesium carbonate (22.5 g, 69.2 mmol) were added to a solution of compound WH-5 (8 g, 23 mmol) and tert-butyl 4-(6-aminopyridin-3-yl)piperazine-1-carboxylate (7.1 g, 25.4 mmol) in 1,4-dioxane (50 mL) in sequence, and the mixture was stirred at 110 ° C for 6 hours under nitrogen protection. The system was cooled to room temperature, diluted with ethyl acetate (100 mL) and water (30 mL), the organic phase was collected, the aqueous phase was extracted twice with ethyl acetate, the organic phases were combined, washed with saturated brine (50 mL), dried over anhydrous sodium sulfate, filtered, concentrated, and the residue was purified by silica gel column chromatography (petroleum ether / ethyl acetate) to obtain compound WH-6 (4.2 g, yield 34%). ESI-MS (m / z): 544.7 [M+H] + .
[0139] Step 6: XPhos Pd G2 (0.5 g, 0.6 mmol) and potassium acetate (1.8 g, 18.7 mmol) were added to a solution of compound WH-6 (3.4 g, 6.3 mmol) and biboric acid pinacol ester (3.2 g, 12.5 mmol) in 1,4-dioxane (40 mL) in sequence, and the mixture was stirred at 90 ° C for 2 hours under nitrogen protection. The system was cooled to room temperature, diluted with ethyl acetate (100 mL) and water (20 mL), the organic phase was collected, the aqueous phase was extracted twice with ethyl acetate, the organic phases were combined, washed with saturated brine (50 mL), dried over anhydrous sodium sulfate, filtered, concentrated, and the residue was purified by silica gel column chromatography (petroleum ether / ethyl acetate) to obtain compound WH-7 (1.8 g, yield 45%). ESI-MS (m / z): 636.2 [M+H] + .
[0140] Step 7: XPhos Pd G2 (0.5 g, 0.6 mmol), XPhos (0.16 g, 0.3 mmol), potassium phosphate (4.2 g, 19.8 mmol) were added to a solution of compound WH-7 (4.2 g, 6.6 mmol) and 7-fluoro-3-iodoimidazo[1,2-a]pyridine (2.1 g, 7.9 mmol) in 1,4-dioxane (10 mL) and water (2 mL) in sequence, and the mixture was stirred at 100 ° C for 3 hours under nitrogen protection. The system was cooled to room temperature, diluted with ethyl acetate (50 mL) and water (10 mL), the organic phase was collected, the aqueous phase was extracted twice with ethyl acetate, the organic phases were combined, washed with saturated brine (30 mL), dried over anhydrous sodium sulfate, filtered, concentrated, and the residue was purified by silica gel column chromatography (petroleum ether / ethyl acetate) to obtain compound WH-8 (1.9 g, yield 45%). ESI-MS (m / z): 644.5 [M+H] + .
[0141] Step 8: Add HCl dioxane solution (2 mL, 4 M) to a solution of compound WH-8 (1.9 g, 2.9 mmol) in dichloromethane (5 mL), and stir the mixture at room temperature for 2 hours. The system was directly concentrated to dryness to obtain compound WH-8 (1.2 g, yield 92%). ESI-MS (m / z): 444.6 [M+H] + .
[0142] Example 1
[0143]
[0144] Step 1: Dissolve compound 1a (100 mg, 0.36 mmol) and (R)-pyrrolidine-3-methanol (36 mg, 0.36 mmol) in NMP (2 mL), add N,N-diisopropylethylamine (93 mg, 0.72 mmol) to the reaction system, then heat the reaction system to 80 ° C and stir overnight. The reaction system is cooled to room temperature, diluted with ethyl acetate, and extracted with saturated brine three times. The organic phase is dried over anhydrous sodium sulfate, filtered, and concentrated. The crude product is purified by silica gel column chromatography (dichloromethane / methanol) to obtain compound 1b (118 mg, yield 92%). ESI-MS (m / z): 358.8 [M+H] + .
[0145] Step 2: Compound 1b (118 mg) was dissolved in acetonitrile (5 mL), 2-iodobenzoic acid (94 mg) was added to the reaction system, and the reaction system was stirred at 80°C for 5 hours. LCMS detected that the substrate reaction was complete. The reaction system was filtered, washed with acetonitrile, and the organic phase was concentrated to obtain compound 1c (103 mg, yield 87%), which was directly used in the next step. ESI-MS (m / z): 356.4 [M+H] + .
[0146] Step 3: Under ice bath conditions, compound 1c (100 mg) and WH (70 mg) were dissolved in dichloroethane (4 mL) and methanol (2 mL), sodium acetate (24 mg) was added to the reaction system, and then the reaction system was stirred for 0.5 hours, and then sodium triacetoxyborohydride (62 mg) was added. The system was stirred at 50 ° C overnight, and the reaction was complete after LCMS monitoring. The reaction solution was diluted with dichloromethane, separated, and the aqueous phase was extracted twice with dichloromethane. The organic phases were combined, concentrated and dried, and the residue was prepared and purified by Prep-HPLC to obtain compound 1 (25 mg, yield 22%). ESI-MS (m / z): 783.8 [M+H] + ; 1 H NMR(500MHz,DMSO-d6)δ11.09(s,1H),9.99(s,1H),9.80–9.47(m,1H),8.87(s,1H),8.74–8.59(m,2H),8.41–8.24(m,1H),8. 10(d,J=3.0Hz,1H),8.04–7.94(m,1H),7.79–7.66(m,2H),7.57(dd,J=9.0,3.0Hz,1H),7.45(d,J=6.1Hz,1H),7.08(d,J=8.9H z,1H),6.96(d,J=2.2Hz,1H),6.85(dd,J=8.6,2.2Hz,1H),5.10–5.04(m,1H),4.45–4.37(m,3H),3.62–3.54(m,2H),3.47–3. 33(m,4H),3.30–3.21(m,3H),3.13–3.04(m,2H),2.94–2.84(m,2H),2.66–2.55(m,2H),2.34–2.19(m,2H),2.07–1.93(m,2H).
[0147] Example 2
[0148]
[0149] Substituting azetidin-3-ylmethanol for (R)-pyrrolidine-3-methanol in the first step of Example 1, using a similar method and reaction steps, compound 2 can be obtained. ESI-MS (m / z): 769.9 [M+H] + ; 1 H NMR (500MHz, DMSO-d6) δ11.04(s,1H),9.85(s,1H),8.76(s,1H),8.56(d,J=8.6Hz,1H),8.45–8.36(m,1H ),8.05–7.97(m,1H),7.80(s,1H),7.70–7.61(m,2H),7.54–7.42(m,2H),7.00–6.93(m,2H),6.79(s,1H) ,6.68–6.62(m,1H),5.08–5.01(m,1H),4.37(s,2H),4.16(t,J=8.1Hz,2H),3.76–3.68(m,2H),3.14–3.0 7(m,4H),3.07–3.02(m,1H),2.93–2.82(m,1H),2.71–2.66(m,2H),2.62–2.52(m,6H),2.03–1.97(m,1H).
[0150] Example 3
[0151]
[0152] By replacing (R)-pyrrolidine-3-methanol in the first step of Example 1 with 4-hydroxymethylpiperidine, compound 3 can be obtained using a similar method and reaction steps. ESI-MS (m / z): 797.3 [M+H] + ; 1H NMR (500MHz, DMSO-d6) δ11.01(s,1H),9.84(s,1H),8.76(s,1H),8.56(d,J=8.6Hz,1H),8.41(t,J=6.6Hz,1H),8.00(s, 1H),7.80(s,1H),7.70–7.62(m,2H),7.54–7.49(m,1H),7.46–7.41(m,1H),7.31(s,1H),7.24(d,J=8.8Hz,1H),7.00–6 .93(m,2H),5.09–4.97(m,1H),4.37(s,2H),4.05(d,J=12.9Hz,2H),3.12(s,4H),2.98(t,J=12.5Hz,2H),2.91–2.81(m ,1H),2.53(s,6H),2.22(d,J=7.0Hz,2H),2.05–1.95(m,1H),1.91–1.86(m,1H),1.85–1.79(m,2H),1.21–1.11(m,2H).
[0153] Example 4
[0154]
[0155] Compound 4 can be obtained by replacing 2-(2,6-dioxopiperidin-3-yl)-4-fluoroiso-1,3-dione in the first step of Example 1 with 2-(2,6-dioxopiperidin-3-yl)-5-fluoroiso-1,3-dione and replacing (R)-pyrrolidine-3-methanol in the first step of Example 1 with 4-hydroxymethylpiperidine using a similar method and reaction steps. ESI-MS (m / z): 797.5 [M+H] + ; 1 H NMR(500MHz,DMSO-d6)δ11.10(s,1H),9.86(s,1H),8.78(s,1H),8.57(d,J=8.6Hz,1H),8.53 –8.18(m,1H),8.02(s,1H),7.82(s,1H),7.77–7.63(m,2H),7.61–7.31(m,4H),7.05–6.89(m ,2H),5.17–5.03(m,1H),4.39(s,2H),3.81–3.61(m,2H),3.14(s,4H),2.95–2.84(m,3H),2. 69–2.56(m,5H),2.32–2.25(m,2H),2.08–1.98(m,2H),1.90–1.75(m,3H),1.40–1.32(m,2H).
[0156] Example 5
[0157]
[0158] Step 1: Dissolve compound WH (300 mg, 0.68 mmol) and bromoacetaldehyde dimethyl acetal (343 mg, 2.0 mmol) in DMF (4 mL), add N, N-diisopropylethylamine (437 mg, 3.4 mmol) to the reaction system, then heat the reaction system to 90 ° C and stir overnight. The reaction system is cooled to room temperature, diluted with dichloromethane, and extracted with saturated brine three times. The organic phase is dried over anhydrous sodium sulfate, filtered, and concentrated. The crude product is purified by silica gel column chromatography (dichloromethane / methanol) to obtain compound 5a (200 mg, yield 56%). ESI-MS (m / z): 532.3 [M+H] + .
[0159] Step 2: Dissolve compound 5a (200 mg, 0.35 mmol) in 1,4-dioxane (2 mL), add HCl dioxane solution (2 mL, 4 M) and water (1 mL) to the reaction system, then heat the reaction system to 50 ° C and stir overnight. The reaction system was cooled to room temperature, concentrated and dried to obtain product 5b (160 mg, yield 98%). ESI-MS (m / z): 486.9 [M+H] + .
[0160] Step 3: Dissolve compound 1a (4g) and 1-tert-butyloxycarbonylpiperazine (5.4g) in NMP (20mL), add N,N-diisopropylethylamine (5.6g) to the reaction system, and then heat the reaction system to 90°C and stir overnight. The reaction system is cooled to room temperature, diluted with ethyl acetate, and extracted with saturated brine three times. The organic phase is dried over anhydrous sodium sulfate, filtered, and concentrated. The crude product is purified by silica gel column chromatography (petroleum ether / ethyl acetate) to obtain compound 5c (4.8g, yield 75%). ESI-MS (m / z): 443.4 [M+H] + .
[0161] Step 4: Add HCl dioxane solution (10 mL, 4 M) to a solution of compound 5c (2.5 g) in 1,4-dioxane (10 mL), and stir the mixture at room temperature for 2 hours. The system was directly spin-dried to obtain compound 5d (1.9 g, yield 99%). ESI-MS (m / z): 343.7 [M+H] + .
[0162] Step 5: Under ice bath conditions, compound 5b (18 mg) and 5d (13 mg) were dissolved in dichloroethane (2 mL) and methanol (1 mL), sodium acetate (6 mg) was added to the reaction system, and then the reaction system was stirred for 0.5 hours, and then sodium triacetoxyborohydride (16 mg) was added. The system was stirred at 50 ° C overnight, and the reaction was complete after LCMS monitoring. The reaction solution was diluted with dichloromethane, separated, and the aqueous phase was extracted twice with dichloromethane. The organic phases were combined, concentrated and dried, and the residue was purified by Prep-HPLC to obtain compound 5 (3 mg, yield 10%). ESI-MS (m / z): 812.4 [M+H] + ; 1 HNMR(500MHz,DMSO-d6)δ11.02(s,1H),9.77(s,1H),8.70(s,1H),8.49(d,J=8.5Hz ,1H),8.37–8.33(m,1H),7.93(d,J=3.0Hz,1H),7.74(s,1H),7.61(d,J=8.5Hz,2H), 7.50–7.15(m,5H),6.94–6.85(m,3H),5.18–4.81(m,1H),4.30(s,2H),3.42–3.34(m ,4H),3.07–3.02(m,5H),2.86–2.78(m,1H),2.55–2.49(m,10H),1.97–1.90(m,2H).
[0163] Example 6
[0164]
[0165] Step 1: Add compound 6a (100 mg), potassium iodide (12 mg) and sodium bicarbonate (61 mg) to DMF (2 mL), add 2-(2-bromoethoxy)ethanol (68 mg) to the reaction system, then heat the reaction system to 80°C and stir overnight. The reaction system was cooled to room temperature, diluted with ethyl acetate, and extracted with saturated brine three times. The organic phase was dried over anhydrous sodium sulfate, filtered, and concentrated. The crude product was purified by silica gel column chromatography (dichloromethane / methanol) to obtain compound 6b (130 mg, yield 98%). ESI-MS (m / z): 363.6 [M+H] + .
[0166] Step 2: Compound 6b (130 mg) was dissolved in acetonitrile (5 mL), 2-iodobenzoic acid (151 mg) was added to the reaction system, and the reaction system was stirred at 80°C for 5 hours. LCMS detected that the substrate reaction was complete. The reaction system was filtered, washed with acetonitrile, and the organic phase was concentrated to obtain compound 6c (105 mg, yield 81%), which was directly used in the next step. ESI-MS (m / z): 361.4 [M+H] + .
[0167] Step 3: Under ice bath conditions, compound WH (40 mg) and 6c (60 mg) were dissolved in dichloroethane (4 mL) and methanol (2 mL), sodium acetate (14 mg) was added to the reaction system, and then the reaction system was stirred for 0.5 hours, and then sodium triacetoxyborohydride (35 mg) was added. The system was stirred at 50 ° C overnight, and the reaction was complete when monitored by LCMS. The reaction solution was diluted with dichloromethane, separated, and the aqueous phase was extracted twice with dichloromethane. The organic phases were combined, concentrated and dried, and the residue was prepared and purified by Prep-HPLC to obtain compound 6 (13 mg, yield 20%). ESI-MS (m / z): 788.9 [M+H] + ; 1 H NMR(500MHz,DMSO-d6)δ11.13(s,1H),9.85(s,1H),8.78(s,1H),8.56(d,J=8.6Hz,1H), 8.43(dd,J=7.6,5.8Hz,1H),7.88–7.80(m,3H),7.69(d,J=8.5Hz,1H),7.55–7.39(m,5H ),7.00–6.95(m,2H),5.17–5.08(m,2H),4.39–4.35(m,5H),3.84–3.76(m,2H),3.66–3. 63(m,1H),3.11–3.05(m,4H),2.93–2.85(m,2H),2.60–2.57(m,4H),2.06–2.01(m,2H).
[0168] Example 7
[0169]
[0170] Step 1: Add compound 6a (100 mg), potassium iodide (12 mg) and sodium bicarbonate (61 mg) to DMF (2 mL), add tert-butyl 5-bromovalerate (95 mg) to the reaction system, then heat the reaction system to 80 ° C and stir overnight. The reaction system is cooled to room temperature, diluted with ethyl acetate, and extracted with saturated brine three times. The organic phase is dried over anhydrous sodium sulfate, filtered, and concentrated. The crude product is purified by silica gel column chromatography (dichloromethane / methanol) to obtain compound 7a (150 mg, yield 95%). ESI-MS (m / z): 431.1 [M+H] + .
[0171] Step 2: Compound 7a (150 mg) was dissolved in dichloromethane (4 mL), and trifluoroacetic acid (2 mL) was added at 0°C. The mixture was stirred at room temperature for 2 hours. The reaction was completed after LCMS monitoring. The reaction solution was concentrated and dried to obtain product 7b (130 mg, yield 99%). ESI-MS (m / z): 375.6 [M+H] + .
[0172] Step 3: Dissolve compound 7b (23 mg) in DMF (2 mL), add 2-(7-azobenzotriazole)-N,N,N',N'-tetramethyluronium hexafluorophosphate (47 mg) under stirring at 0°C, and after 10 minutes, add DIPEA (40 mg) and compound WH (30 mg) in sequence, warm to room temperature and stir overnight. The reaction system was filtered and purified by Prep-HPLC to obtain compound 7 (15 mg, yield 30%). ESI-MS (m / z): 800.4 [M+H] + ; 1H NMR (500MHz, DMSO-d6) δ11.04(s,1H),9.82(s,1H),8.72(s,1H),8.51(d,J=8.6Hz,1H),8.45–8.41(m,1H),7.95(d,J=3.0Hz,1H) ,7.89(s,1H),7.77(d,J=8.3Hz,1H),7.63(d,J=8.6Hz,1H),7.60–7.56(m,1H),7.43–7.40(m,1H),7.37(d,J=2.3Hz,1H),7.29(d d,J=8.4,2.3Hz,1H),7.06–7.02(m,1H),6.92(d,J=8.9Hz,1H),5.09–5.00(m,1H),4.31(s,2H),4.14(t,J=6.4Hz,2H),3.55(t,J =4.8Hz,4H),3.07–2.98(m,5H),2.86–2.78(m,1H),2.59–2.46(m,2H),2.00–1.92(m,2H),1.76–1.71(m,2H),1.65–1.60(m,2H).
[0173] Example 8
[0174]
[0175] The first step: Compound 8a (2.1 g) and tert-butyl 4-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolane-2-yl)phenyl)piperazine-1-carboxylate (2 g) were dissolved in dioxane (24 mL) and water (8 mL), and then Pd(dppf)Cl2 (376 mg) and cesium carbonate (5 g) were added, and the reaction was stirred at 100 ° C for 3 hours under a nitrogen atmosphere. The reaction system was cooled to room temperature, ethyl acetate (50 mL) and water (30 mL) were added to dilute, the organic phase was collected, the aqueous phase was extracted twice with ethyl acetate, the organic phases were combined, washed with saturated brine, dried over anhydrous sodium sulfate, filtered, concentrated, and the crude product was purified by silica gel column chromatography (petroleum ether / ethyl acetate) to obtain compound 8b (2.6 g, yield 91%). ESI-MS (m / z): 552.2 [M+H] + .
[0176] Step 2: Compound 8b (2.6 g) was dissolved in methanol (20 mL) and ethyl acetate (20 mL), and then palladium hydroxide (1.6 g) was added. The system was stirred overnight at room temperature under a hydrogen atmosphere. The reaction solution was filtered and concentrated by rotary evaporation. The crude product was purified by silica gel column chromatography (petroleum ether / ethyl acetate) to obtain compound 8c (1.7 g, yield 96%). ESI-MS (m / z): 374.8 [M+H]+ .
[0177] Step 3: Compound 8c (1.7 g) was dissolved in 1,4-dioxane (5 mL), and then HCl dioxane solution (5 mL, 4 M) was added. The mixture was stirred at room temperature for 2 hours. LCMS monitored the reaction to be complete. The reaction solution was concentrated and dried to obtain product 8d (1.5 g, yield 99%). ESI-MS (m / z): 274.5 [M+H] + .
[0178] Step 4: Under ice bath conditions, compound 5b (30 mg) and 8d (19 mg) were dissolved in dichloroethane (2 mL) and methanol (1 mL), sodium acetate (10 mg) was added to the reaction system, and then the reaction system was stirred for 0.5 hours, and then sodium triacetoxyborohydride (26 mg) was added. The system was stirred at 50 ° C overnight, and the reaction was complete after LCMS monitoring. The reaction solution was diluted with dichloromethane, separated, and the aqueous phase was extracted twice with dichloromethane. The organic phases were combined, concentrated and dried, and the residue was prepared and purified by Prep-HPLC to obtain compound 8 (5 mg, yield 11%). ESI-MS (m / z): 743.7 [M+H] + ; 1 HNMR(500MHz,DMSO-d6)δ10.71(s,1H),9.77(s,1H),8.70(s,1H),8.49(d,J=8.5Hz,1H ),8.35(t,J=6.7Hz,1H),7.92(d,J=2.9Hz,1H),7.74(s,1H),7.61(d,J=8.6Hz,1H),7.5 0–7.34(m,2H),7.01–6.79(m,6H),4.30(s,2H),3.66(dd,J=11.0,4.9Hz,1H),3.10–2. 93(m,9H),2.54–2.48(m,7H),2.46–2.45(m,2H),2.40–2.35(m,3H),2.09–1.90(m,3H).
[0179] Example 9
[0180]
[0181] Step 1: Dissolve compound 8d (50 mg) and bromoacetic acid (28 mg) in DMF (2 mL), add 2-(7-azobenzotriazole)-N,N,N',N'-tetramethyluronium hexafluorophosphate (139 mg) and DIPEA (71 mg) under stirring at 0°C, warm to room temperature and stir overnight. Dilute the reaction solution with ethyl acetate, separate the layers, wash the organic phase with saturated brine, concentrate and spin dry to obtain compound 9a (70 mg, yield 97%). ESI-MS (m / z): 394.5 [M+H] + .
[0182] Step 2: Compound 9a (50 mg) and WH (40 mg) were dissolved in DMF (2 mL), and then DIPEA (58 mg) was added, the temperature was raised to 80°C, and stirred overnight. The reaction system was filtered and purified by Prep-HPLC to obtain compound 9 (15 mg, yield 30%). ESI-MS (m / z): 757.7 [M+H] + ; 1 H NMR(500MHz,DMSO-d6)δ10.71(s,1H),9.77(s,1H),8.70(s,1H),8.54–8.43 (m,1H),8.35(t,J=6.7Hz,1H),7.99–7.87(m,1H),7.74(s,1H),7.66–7.55(m ,1H),7.48–7.32(m,2H),7.03–6.82(m,5H),4.30(s,2H),3.78–3.49(m,4H), 3.22–3.15(m,5H),3.14–2.98(m,8H),2.62–2.49(m,4H),2.11–1.85(m,3H).
[0183] Example 10
[0184]
[0185] Step 1: Dissolve compound 10a (200 mg) in tert-butyl alcohol (5 mL), add di-tert-butyl dicarbonate (468 mg) and DMAP (53 mg) under stirring, and stir at room temperature overnight. Dilute the reaction solution with ethyl acetate, wash with 1M hydrochloric acid, saturated sodium bicarbonate solution, and saturated brine in sequence, concentrate the organic phase and spin dry to obtain compound 10b (260 mg, yield 99%). ESI-MS (m / z): 243.3 [M+H] + .
[0186] Step 2: Compound 10b (260 mg) was dissolved in tetrahydrofuran (4 mL) and water (2 mL), and then lithium hydroxide (45 mg) was added and stirred at room temperature overnight. The system was adjusted to pH = 2 with hydrochloric acid, and then filtered. The filter cake was washed with water, and the filter cake was collected and dried to obtain compound 10c (235 mg, yield 96%). ESI-MS (m / z): 229.2 [M+H] + .
[0187] Step 3: Dissolve compound 10c (41 mg) and 8d (50 mg) in DMF (3 mL), add 2-(7-azobenzotriazole)-N,N,N',N'-tetramethyluronium hexafluorophosphate (139 mg) and DIPEA (118 mg) at 0°C with stirring, warm to room temperature, and stir overnight. Dilute the reaction solution with ethyl acetate, separate the layers, wash the organic phase with saturated brine, concentrate and spin dry to obtain compound 10d (52 mg, yield 59%). ESI-MS (m / z): 484.6 [M+H] + .
[0188] Step 4: Compound 10d (52 mg) was dissolved in dichloromethane (2 mL), and then trifluoroacetic acid (1 mL) was added. The system was stirred at room temperature for 2 hours. After the reaction was completed, the mixture was dried under reduced pressure to obtain compound 10e (45 mg, yield 98%). ESI-MS (m / z): 428.4 [M+H] + .
[0189] Step 5: Compound 10e (45 mg) and WH (46 mg) were dissolved in DMF (3 mL), 2-(7-azobenzotriazole)-N,N,N',N'-tetramethyluronium hexafluorophosphate (80 mg) and DIPEA (68 mg) were added under stirring at 0°C, the temperature was raised to room temperature, and stirred overnight. The reaction system was filtered and purified by Prep-HPLC to obtain compound 10 (9 mg, yield 10%). ESI-MS (m / z): 853.9 [M+H] + . 1H NMR (500MHz, DMSO-d6) δ10.79(s,1H),9.89(s,1H),8.79(s,1H),8.58(d,J=8.6Hz,1H),8. 43(dd,J=7.6,5.8Hz,1H),8.03(d,J=3.0Hz,1H),7.82(s,1H),7.70(d,J=8.6Hz,1H),7.58 –7.45(m,2H),7.13–7.04(m,2H),7.01–6.91(m,4H),4.39(s,2H),3.80–3.48(m,9H),3.15 –3.02(m,8H),2.73–2.60(m,3H),2.18–1.99(m,3H),1.77–1.69(m,4H),1.56–1.48(m,4H).
[0190] Embodiment 11
[0191]
[0192] Step 1: Dissolve compound 11a (2.2 g) and 3-bromopiperidine-2,6-dione (2.3 g) in DMF (20 mL), then add sodium bicarbonate (2 g), warm to 80 ° C, and stir overnight. The reaction solution was diluted with ethyl acetate, separated, the organic phase was washed with saturated brine, dried over anhydrous sodium sulfate, filtered, concentrated, and the crude product was purified by silica gel column chromatography (petroleum ether / ethyl acetate) to obtain compound 11b (1.1 g, yield 32%). ESI-MS (m / z): 389.4 [M+H] + .
[0193] Step 2: Add HCl dioxane solution (7 mL, 4 M) to a solution of compound 11b (1.1 g) in dichloromethane (15 mL), and stir the reaction solution at room temperature for 2 hours. The system was directly spin-dried to obtain compound 11c (840 mg, yield 95%). ESI-MS (m / z): 289.7 [M+H] + .
[0194] Step 3: Under ice bath conditions, compound 5b (30 mg) and 11c (18 mg) were dissolved in dichloroethane (2 mL) and methanol (1 mL), sodium acetate (10 mg) was added to the reaction system, and then the reaction system was stirred for 0.5 hours, and then sodium triacetoxyborohydride (26 mg) was added. The system was stirred at 50 ° C overnight, and the reaction was complete after LCMS monitoring. The reaction solution was diluted with dichloromethane, separated, and the aqueous phase was extracted twice with dichloromethane. The organic phases were combined, concentrated and dried, and the residue was prepared and purified by Prep-HPLC to obtain compound 11 (4 mg, yield 9%). ESI-MS (m / z): 758.5 [M+H]+ ; 1 HNMR(500MHz,DMSO-d6)δ10.69(s,1H),9.77(s,1H),8.70(s,1H),8.49(d,J=8.6Hz,1H),8.35(t,J=6.6H z,1H),7.92(d,J=2.9Hz,1H),7.74(s,1H),7.61(d,J=8.6Hz,1H),7.51–7.31(m,2H),6.95–6.47(m,6H), 5.31(d,J=7.3Hz,1H),4.30(s,2H),4.20–4.06(m,1H),3.07–2.98(m,4H),2.93–2.80(m,4H),2.71–2.61 (m,1H),2.58–2.46(m,9H),2.09–1.90(m,2H),1.84–1.70(m,1H),1.50–1.33(m,1H),1.18–1.15(m,2H).
[0195] Example 12
[0196]
[0197] Step 1: A mixture of compound 12a (3.5 g) and glyoxylic acid (2.5 g) was stirred at 105°C for 16 hours, then cooled to room temperature, and water (25 mL) and dichloromethane (25 mL) were added. The mixture was adjusted to alkalinity with aqueous ammonia, separated, the aqueous phase was washed with dichloromethane, hydrazine hydrate (6.37 g) was added to the aqueous phase, and the system was stirred at 100°C for 4 hours. The mixture was cooled to room temperature, filtered, and the residue was purified by silica gel column chromatography (petroleum ether / ethyl acetate) to obtain compound 12b (1 g, yield 23%). ESI-MS (m / z): 259.3 [M+H] + .
[0198] Step 2: A mixture of compound 12b (160 mg) and piperidine (534 mg) was stirred at 150°C for 6 hours, then cooled to room temperature, water (10 mL) and ethyl acetate (20 mL) were added, the liquids were separated, the aqueous phase was extracted twice with ethyl acetate, the organic phases were combined, washed with saturated brine, dried over anhydrous sodium sulfate, filtered, concentrated, and the crude product was purified by silica gel column chromatography (dichloromethane / methanol) to obtain compound 12c (41 mg, yield 21%). ESI-MS (m / z): 325.6 [M+H] + .
[0199] Step 3: Under ice bath conditions, compound 5b (14 mg) and 12c (10 mg) were dissolved in dichloroethane (2 mL) and methanol (1 mL), sodium acetate (5 mg) was added to the reaction system, and then the reaction system was stirred for 0.5 hours, and then sodium triacetoxyborohydride (13 mg) was added. The system was stirred at 50 ° C overnight, and the reaction was complete after LCMS monitoring. The reaction solution was diluted with dichloromethane, separated, and the aqueous phase was extracted twice with dichloromethane. The organic phases were combined, concentrated and dried, and the residue was prepared and purified by Prep-HPLC to obtain compound 12 (4 mg, yield 20%). ESI-MS (m / z): 794.5 [M+H] + ; 1 H NMR (500MHz, DMSO-d6) δ13.26(s,1H),9.86(s,1H),8.78(s,1H),8.57(d,J=8.6Hz,1H),8.43(t,J=6.7Hz,1H),8.19–7.97(m,4H),7.82( s,1H),7.74–7.61(m,2H),7.56–7.42(m,2H),7.07–6.91(m,3H),4.38(s,2H),3.17–3.09(m,4H),3.01–2.89(m,4H),2.75–2.54(m,12H).
[0200] Example 13
[0201]
[0202] Step 1: A mixture of compound 13a (200 mg), ethyl acrylate (108 mg), and DBU (108 mg) was stirred at 90°C for 3 hours, then diluted with ethyl acetate, the organic phase was washed with saturated brine, dried over anhydrous sodium sulfate, filtered, and concentrated. The crude product was purified by silica gel column chromatography (petroleum ether / ethyl acetate) to obtain compound 13b (235 mg, yield 86%). ESI-MS (m / z): 378.4 [M+H] + .
[0203] Step 2: Compound 13b (235 mg) was dissolved in toluene (3 mL), and then sodium bicarbonate (93 mg) and bromocyanogen (122 mg) were added and stirred at room temperature for 3 hours. The reaction solution was diluted with ethyl acetate, and the organic phase was washed with saturated brine, dried over anhydrous sodium sulfate, filtered, and concentrated. The crude product was purified by silica gel column chromatography (petroleum ether / ethyl acetate) to obtain compound 13c (145 mg, yield 65%). ESI-MS (m / z): 403.4 [M+H] + .
[0204] Step 3: Compound 13c (145 mg) was dissolved in toluene (5 mL), and then acetaldehyde oxime (64 mg) and indium chloride (24 mg) were added, and the mixture was refluxed and stirred for 1 hour. The reaction solution was cooled to room temperature, diluted with ethyl acetate, and the organic phase was washed with saturated brine, dried over anhydrous sodium sulfate, filtered, and concentrated to obtain compound 13d (73 mg, yield 48%). ESI-MS (m / z): 421.5 [M+H] + .
[0205] Step 4: Compound 13d (73 mg) was dissolved in acetonitrile (3 mL), and then Triton B (40% in MeOH, 0.2 mL) was added and stirred at 60°C for 1 hour. The reaction solution was cooled to room temperature, diluted with ethyl acetate, and the organic phase was washed with saturated brine, dried over anhydrous sodium sulfate, filtered, and concentrated to obtain compound 13e (60 mg, yield 88%). ESI-MS (m / z): 375.2 [M+H] + .
[0206] Step 5: Add HCl dioxane solution (1 mL, 4 M) to a solution of compound 13e (30 mg) in 1,4-dioxane (1 mL), and stir the mixture at room temperature for 2 hours. The system was directly spin-dried to obtain compound 13f (20 mg, yield 95%). ESI-MS (m / z): 275.3 [M+H] + .
[0207] Step 6: Under ice bath conditions, compound 5b (37 mg) and 13f (20 mg) were dissolved in dichloroethane (2 mL) and methanol (1 mL), sodium acetate (13 mg) was added to the reaction system, and then the reaction system was stirred for 0.5 hours, and then sodium triacetoxyborohydride (32 mg) was added. The system was stirred at 50 ° C overnight, and the reaction was complete when monitored by LCMS. The reaction solution was diluted with dichloromethane, separated, and the aqueous phase was extracted twice with dichloromethane. The organic phases were combined, concentrated and dried, and the residue was prepared and purified by Prep-HPLC to obtain compound 13 (3 mg, yield 5%). ESI-MS (m / z): 744.8 [M+H] + ; 1HNMR(500MHz,DMSO-d6)δ10.27(s,1H),9.85(s,1H),8.78(s,1H),8.56(d,J =8.6Hz,1H),8.48–8.40(m,1H),8.00(d,J=3.1Hz,1H),7.82(s,1H),7.69(d ,J=8.5Hz,1H),7.58–7.42(m,2H),7.16(d,J=9.0Hz,2H),7.03–6.88(m,4H) ,4.38(s,2H),3.70(t,J=6.7Hz,2H),3.18–3.08(m,9H),2.71–2.53(m,13H).
[0208] Embodiment 14
[0209]
[0210] Step 1: Compound 14a (500 mg) was dissolved in acetic acid (3 mL) and water (3 mL), and then acrylic acid (207 mg) was added, and the mixture was stirred at 105°C for 16 hours. The reaction solution was cooled to room temperature, poured into ice water, and the pH was adjusted to 5.0 with saturated sodium bicarbonate solution, and then extracted with ethyl acetate. The organic phase was washed with saturated brine, dried over anhydrous sodium sulfate, filtered, and concentrated to obtain compound 14b (650 mg, yield 98%). ESI-MS (m / z): 298.1 [M+H] + .
[0211] Step 2: Compound 14b (600 mg) was dissolved in acetic acid (5 mL), and then urea (241 mg) was added. The mixture was stirred at 120°C for 4 hours, and then concentrated hydrochloric acid (1 mL) was added and stirred for half an hour. The reaction solution was cooled to room temperature, poured into ice water, and the pH was adjusted to 7.0 with saturated sodium bicarbonate solution, and then extracted with dichloromethane. The organic phase was washed with water and saturated brine, dried over anhydrous sodium sulfate, filtered, and concentrated. The crude product was purified by silica gel column chromatography (methanol / dichloromethane) to obtain compound 14c (126 mg, yield 19%). ESI-MS (m / z): 323.1 [M+H] + .
[0212] Step 3: Compound 14c (110 mg) and 4-(dimethoxymethyl)-piperidine (108 mg) were dissolved in dioxane (5 mL), and then RuPhos Pd G2 (40 mg) and cesium carbonate (332 mg) were added, and the mixture was stirred at 110 ° C for 16 hours under nitrogen. After the reaction was completed, the system was filtered, washed with dichloromethane, and the organic phase was concentrated. The crude product was purified by silica gel column chromatography (methanol / dichloromethane) to obtain compound 14d (30 mg, yield 23%). ESI-MS (m / z): 402.4 [M+H] + .
[0213] Step 4: Dissolve 14d (30 mg) in 1,4-dioxane (1 mL), add HCl dioxane solution (1 mL, 4 M) and water (1 mL) to the reaction system, then heat the reaction system to 50 ° C and stir overnight. The reaction system was cooled to room temperature and concentrated to dryness to obtain compound 14e (26 mg, yield 98%). ESI-MS (m / z): 356.3 [M+H] + .
[0214] Step 5: Under ice bath conditions, compound 14e (26 mg) and WH (37 mg) were dissolved in dichloroethane (4 mL) and methanol (2 mL), sodium acetate (15 mg) was added to the reaction system, and then the reaction system was stirred for 0.5 hours, and then sodium triacetoxyborohydride (36 mg) was added. The system was stirred at 50 ° C overnight, and the reaction was complete when monitored by LCMS. The reaction solution was diluted with dichloromethane, separated, and the aqueous phase was extracted twice with dichloromethane. The organic phases were combined, concentrated and dried, and the residue was prepared and purified by Prep-HPLC to obtain compound 14 (12 mg, yield 18%). ESI-MS (m / z): 783.8 [M+H] + ; 1H NMR (500MHz, DMSO-d6) δ10.51(s,1H),9.86(s,1H),8.78(s,1H),8.57(d,J=8.5Hz,1H),8.43(dd,J=7.6,5.7Hz,1H), 8.01(d,J=3.0Hz,1H),7.82(s,1H),7.69(d,J=8.6Hz,1H),7.53(dd,J=10.1,2.6Hz,1H),7.49–7.40(m,2H),7.01–6. 95(m,2H),6.92(dd,J=9.2,1.9Hz,1H),6.82(d,J=1.9Hz,1H),4.38(s,2H),3.94–3.87(m,5H),3.87–3.78(m,2H),3. 16–3.08(m,4H),2.82–2.71(m,4H),2.58–2.52(m,4H),2.25(d,J=7.1Hz,2H),1.92–1.77(m,2H),1.34–1.26(m,3H).
[0215] Experimental Example 1: Detection of the ability of compounds to degrade HPK1 protein
[0216] The required reagents are as follows:
[0217]
[0218]
[0219] Experimental procedures
[0220] The specific operation is as follows: Jurkat E6-1 (hereinafter referred to as Jurkat) cells are seeded at 2,500,000 cells / well in a Corning 24-well plate (Catalog No. 3524) in cell culture medium [RPMI 1640 (BI, 01-100-1ACS), 10% heat-inactivated FBS (BI, 04-002-1A), 1% Penicillin-Streptomycin (BI, 03-031-1B)] at a volume of 1 mL / well. Jurkat cells were treated with compounds diluted in 0.2% DMSO according to the following dilution scheme: (1) 3 μL of compound stock solution (10 mM concentration) was transferred to 1497 μL of culture medium to prepare a 20 μM compound solution; (2) starting from 20 μM, 10-fold dilutions were made in 0.2% DMSO for a total of 6 doses; (3) 1 mL of each concentration of compound solution was added to the cells (final compound concentrations were 0, 1, 10, 100, 1000, 10000 nM) and incubated for 20 h. Collect the cells in a 15 mL centrifuge tube and centrifuge at 300 g for five minutes. Discard the culture medium, add 3 mL of 4°C pre-cooled PBS to wash the cells and discard the washing solution. Add an appropriate amount of RIPA lysis buffer (containing Protease and Phosphatase Inhibitor Cocktail) according to the cell volume, mix well and place on ice for 30 minutes for lysis. Oscillate and mix every 10 minutes, then centrifuge at 20,000 rpm for 30 minutes at 4°C. Transfer the supernatant after centrifugation to a new centrifuge tube and use Pierce TMRapid Gold BCA Protein Assay Kit (A53225) was used to quantify protein concentration. An appropriate amount of SDS-PAGE loading buffer was added to the protein sample, and the sample was heated in a boiling water bath for 5 minutes to fully denature the protein, and then stored at -20°C for later use. Precast gel (Genscript, M00655 or M00657) was used for electrophoresis at 120V, and the membrane was transferred at 300mA for 100min at 4°C. After the transfer, the protein membrane was immediately placed in 5% skim milk diluted with TBST, and slowly shaken on a shaker, and blocked at room temperature for 1h. Refer to the instructions of HPK1 Rabbit mAb (CST, 53453S) and GAPDH (D16H11) Rabbit Monoclonal antibody (CST, 5174S), dilute the primary antibody according to the recommended ratio, incubate at 4°C with slow shaking overnight, and then wash with TBST 3 times, 10 min / time; select Goat Anti-Rabbit IgG (H&L)-HRP Conjugated (Thermofisher, G-21234) according to the primary antibody, refer to the instructions of the secondary antibody, dilute the secondary antibody according to the recommended ratio, incubate at room temperature with slow shaking for 1 hour, and wash with TBST 3 times, 10 min / time; add ECL luminescent solution, observe the results with a developer, quantify the Western results with Image J software, and calculate the HPK1 degradation rate (degradation rate = 1-drug group / control group) and the half-degradation concentration DC by comparing with the control group without compound addition. 50 The experimental results are shown in the following table:
[0221]
[0222]
[0223] It can be seen from the results in the above table that the compounds of the present invention can significantly degrade HPK1 protein in Jurkat cells.
[0224] Experimental Example 2: Detection of the ability of compounds to stimulate the secretion of cytokine interleukin-2 (IL-2) by human PBMC cells and the effect of compounds on the viability of human PBMC cells
[0225] The reagents required are as follows
[0226]
[0227] Experimental cell source information:
[0228] Manufacturer batch Product Specifications Shanghai Xuanfeng Biotechnology Co., Ltd. SC12132W / XCWBC6037W 10 / 25million / vial
[0229] Experimental procedures
[0230] The specific operation is as follows: After human PBMC is taken out of liquid nitrogen according to standard operation, it is placed in a 37°C water bath for thawing and recovery, and the cells are resuspended in RPMI 1640 medium (containing 10% FBS in this experiment), centrifuged and washed twice; then the human PBMC cells are resuspended in RPMI 1640 medium for use. The compound powder is dissolved to 10mM with DMSO, 2μL of the compound is added to 998μL RPMI 1640 medium, and the highest concentration point is obtained after vortex mixing. The compound solution is gradually diluted 5 times with 0.2% DMSO medium, for a total of 8 concentration points. The RPMI 1640 medium solution containing 0.1% DMSO was used as a control. In a Corning 96-well cell culture plate (Cat. No.: 3599), 90μL of 0.5×10 5 The culture medium of human PBMC cells was then added with an equal volume of compound dilution. The control group was added with RPMI 1640 culture medium containing 0.2% DMSO and incubated in a 37°C cell culture incubator (Thermo Fisher Scientific, model: 3111) for 1 hour. Then, a final concentration of 0.37-1.1μg / ml Anti-human CD3 Antibody (adjusted according to different batches of human PBMC) and 1μg / ml Anti-human CD28Antibody antibody were added and incubated in a 37°C cell culture incubator for 20 hours. The Human IL-2DuoSet ELISA KIT was used to detect the IL-2 content in the cell supernatant. The Human IL-2DuoSet ELISA test was performed according to the operating instructions of the kit. The data uses the highest multiple ratio of the stimulation signal of the compound to the signal of 0.1% DMSO and the half-effective concentration EC 50 Description. Collect cells and use CellTiter- The Luminescent Cell Viability Assay kit was used to detect cell viability. The cell viability data was calculated using the half inhibitory concentration (IC) of the compound. 50 describe.
[0231] The test results of the compounds' ability to stimulate the secretion of cytokine interleukin-2 (IL-2) by human PBMC cells and the effects of the compounds on the viability of human PBMC cells are shown in the following table:
[0232]
[0233]
[0234] It can be seen from the results in the above table that the compounds of the present invention can significantly stimulate human PBMC cells to secrete cytokine interleukin-2 (IL-2) and have little effect on the viability of human PBMC cells.
Claims
1. A compound having the structure of formula (I), or a stereoisomer, tautomer, solvate, pharmaceutically acceptable salt, metabolite, isotope derivative, N-oxide or prodrug thereof: in: X 1 and X 2 Each independently represents CH, CF or N; R 1 represents an optionally substituted phenyl group or an optionally substituted 5-11-membered heteroaryl group; R a and R b Each independently represents hydrogen, fluorine, C1-C3 alkyl, C3-C6 cycloalkyl, R a , R b It can form a 3-6 membered ring with the carbon atom to which it is connected, can contain 0-2 heteroatoms selected from N, O, S, and can be a spiro ring or a bridged ring; Ring A represents a benzene ring, a 5-9 membered heteroaromatic ring or a 9-10 membered heterocyclic ring; R 2 Each independently represents halogen, -R, -(C0-C3)alkylene-cyano, -(C0-C3)alkylene-OR, -(C0-C3)alkylene-NR2, -(C0-C3)alkylene-S(O2)R, -(C0-C3)alkylene-C(O)R, -(C0-C3)alkylene-(C3-C6)cycloalkyl, -(C0-C3)alkylene-4-7 membered heterocycloalkyl, and the alkyl, haloalkyl, cycloalkyl and heterocycloalkyl may be independently and optionally substituted by 0, 1 or 2 of the following substituents: halogen, cyano, -R, -OR, -NR2, -S(O2)R; or two R on adjacent A ring atoms 2 Together with the ring atoms connected to it, it can further form a ring; R each independently represents hydrogen, C1-C3 alkyl, C1-C3 haloalkyl; ULM is selected from the following structures: Among them, X 3 , X 4 , X 5 , X 6 and X 8 Each independently represents CH, N or CR 3 , where R 3 Each independently represents H, fluorine, chlorine, methyl, methoxy, trifluoromethyl; X 7 Each independently represents -CH2- or -C(O)-; X 9 each independently represents -NH-, -N(Me)- or -O-; X 10 Each independently represents N or CH; X 11 Each independently represents -O-, -NH-, -N(Me)-, -CH2- or -C(Me)2-; Y each independently represents CH, CD, CMe or N; Z each independently represents a bond, -NH-, -O- or -CH2-; L means -C1~C 21 Alkylene-, optionally, wherein 0, 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 alkylene groups can be independently replaced by a group selected from the following: -4-12 membered heterocycloalkyl-, -3-12 membered cycloalkyl-, -O-, -NR L -, -C=C-, -C≡C-, -C(O)-, N(R L )-、-C(O)N(R L )-、-N(R L )C(O)-, wherein the heterocycloalkyl or cycloalkyl may be optionally substituted by 0, 1, 2, 3 or 4 of the following substituents: halogen, hydroxy, amino, methyl or oxo (=O), and the R L Each independently represents H, C1-C3 alkyl; L may be optionally substituted with 0, 1, 2, 3 or 4 of the following substituents: halogen, C1-C3 alkyl, C3-C6 cycloalkyl, -(C0-C3)alkylene-OR, -(C0-C3)alkylene-NR2, -(C0-C3)alkylene-SR or oxo (=O); p represents 0, 1 or 2.
2. The compound according to claim 1, or its stereoisomer, tautomer, solvate, pharmaceutically acceptable salt, metabolite, isotope derivative, N-oxide or prodrug, characterized in that: X 1 represents CH or N; preferably, X 1 Indicates CH.
3. The compound according to claim 1 or 2, or its stereoisomer, tautomer, solvate, pharmaceutically acceptable salt, metabolite, isotope derivative, N-oxide or prodrug, characterized in that: X 2 represents CH or N; preferably, X 2 Indicates CH.
4. A compound according to any preceding claim, or a stereoisomer, tautomer, solvate, pharmaceutically acceptable salt, metabolite, isotopic derivative, N-oxide or prodrug thereof, characterized in that X 1 Indicates CH, X 2 Indicates CH.
5. A compound according to any preceding claim, or a stereoisomer, tautomer, solvate, pharmaceutically acceptable salt, metabolite, isotopic derivative, N-oxide or prodrug thereof, characterized in that R 1 The phenyl or heteroaryl group may be optionally substituted by 0, 1, 2 or 3 substituents selected from the group consisting of hydrogen, halogen, -(C0-C3)alkylene-hydroxy, -(C0-C3)alkylene-amino, -(C0-C3)alkylene-cyano, -(C0-C3)alkylene-(C1-C3)alkyl, -(C0-C3)alkylene-(C1-C3)alkoxy, -(C0-C3)alkylene-(C1-C3)haloalkyl, -(C0-C3)alkylene-(C3-C6)cycloalkyl, and -(C0-C3)alkylene-4-7 membered heterocycloalkyl.
6. A compound according to any preceding claim, or a stereoisomer, tautomer, solvate, pharmaceutically acceptable salt, metabolite, isotopic derivative, N-oxide or prodrug thereof, characterized in that R 1 The phenyl or heteroaryl may be optionally substituted by 0, 1, 2 or 3 substituents selected from the group consisting of hydrogen, halogen, hydroxy, amino, cyano, C1-C3 alkyl, C1-C3 alkoxy, C1-C3 haloalkyl, C3-C6 cycloalkyl, 4-7 membered heterocycloalkyl.
7. A compound according to any preceding claim, or a stereoisomer, tautomer, solvate, pharmaceutically acceptable salt, metabolite, isotopic derivative, N-oxide or prodrug thereof, characterized in that R 1 represents a 5-11 membered heteroaryl group, which may be optionally substituted by 0, 1 or 2 of the following substituents: hydrogen, halogen, hydroxy, amino, cyano, methyl, methoxy, fluoromethyl; preferably, R 1 express More preferably, R 1 express 8. A compound according to any preceding claim, or a stereoisomer, tautomer, solvate, pharmaceutically acceptable salt, metabolite, isotopic derivative, N-oxide or prodrug thereof, characterized in that R a and R b Each independently represents hydrogen, fluorine, or methyl; preferably, R a and R b Both represent hydrogen.
9. A compound according to any preceding claim, or a stereoisomer, tautomer, solvate, pharmaceutically acceptable salt, metabolite, isotopic derivative, N-oxide or prodrug thereof, characterized in that Ring A represents a 5-6 membered heteroaromatic ring or a 9-10 membered heterocyclic ring; preferably, ring A represents a pyridine ring, a pyrimidine ring, a pyrazole ring, or a pyridopiperidine ring; more preferably, A represents a pyridine ring.
10. A compound according to any preceding claim, or a stereoisomer, tautomer, solvate, pharmaceutically acceptable salt, metabolite, isotopic derivative, N-oxide or prodrug thereof, characterized in that R 2 Each independently represents halogen, cyano, -R, -OR, -NR2, -S(O2)R, -C(O)R, C3-C6 cycloalkyl, 4-7 membered heterocycloalkyl, and the alkyl, haloalkyl, cycloalkyl and heterocycloalkyl may be independently and optionally substituted by 0, 1 or 2 of the following substituents: halogen, cyano, -R, -OR, -NR2, -S(O2)R; 11. A compound according to any preceding claim, or a stereoisomer, tautomer, solvate, pharmaceutically acceptable salt, metabolite, isotopic derivative, N-oxide or prodrug thereof, characterized in that R 2 Each independently represents halogen, cyano, -R, -OR, -NR2, C1-C3 alkyl, C3-C6 cycloalkyl, 4-7 membered heterocycloalkyl, and the alkyl, haloalkyl, cycloalkyl and heterocycloalkyl may be independently and optionally substituted by 0, 1 or 2 of the following substituents: halogen, cyano, -R, -OR, -NR2, -S(O2)R; preferably, R each independently represents hydrogen, methyl, trifluoromethyl.
12. A compound according to any preceding claim, or a stereoisomer, tautomer, solvate, pharmaceutically acceptable salt, metabolite, isotopic derivative, N-oxide or prodrug thereof, characterized in that p represents 0 or 1.
13. A compound according to any preceding claim, or a stereoisomer, tautomer, solvate, pharmaceutically acceptable salt, metabolite, isotopic derivative, N-oxide or prodrug thereof, characterized in that express The end marked with * is connected to the N side of NH of formula (I), and the end marked with ** is connected to the L end of formula (I); preferably, express The end marked with * is connected to the N side of NH of formula (I), and the end marked with ** is connected to the L end of formula (I); more preferably, express The end marked with * is connected to the N side of NH of formula (I), and the end marked with ** is connected to the L end of formula (I).
14. A compound according to any preceding claim, or a stereoisomer, tautomer, solvate, pharmaceutically acceptable salt, metabolite, isotopic derivative, N-oxide or prodrug thereof, characterized in that ULM is selected from the following structures: Where R 3 Each independently represents H, fluorine, chlorine, methyl, methoxy or trifluoromethyl.
15. A compound according to any preceding claim, or a stereoisomer, tautomer, solvate, pharmaceutically acceptable salt, metabolite, isotopic derivative, N-oxide or prodrug thereof, characterized in that ULM is selected from the following structures:
16. A compound according to any preceding claim, or a stereoisomer, tautomer, solvate, pharmaceutically acceptable salt, metabolite, isotopic derivative, N-oxide or prodrug thereof, characterized in that L means -C3~C 18 Alkylene-, more preferably L represents -C3~C 15 Alkylene-, optionally, wherein 0, 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 alkylene groups can be independently replaced by a group selected from the following: -4-12 membered heterocycloalkyl-, -3-12 membered cycloalkyl-, -O-, -NR L -, -C=C-, -C≡C-, -C(O)-, N(R L )-、-C(O)N(R L )-、-N(R L )C(O)-, wherein the heterocycloalkyl or cycloalkyl may be optionally substituted by 0, 1, 2, 3 or 4 of the following substituents: halogen, hydroxy, amino, methyl or oxo (=O), and the R L Each independently represents H or C1-C3 alkyl. L may be optionally substituted with 0, 1, 2, 3 or 4 of the following substituents: fluoro, hydroxy, methyl or oxo (=0).
17. A compound according to any preceding claim, or a stereoisomer, tautomer, solvate, pharmaceutically acceptable salt, metabolite, isotopic derivative, N-oxide or prodrug thereof, characterized in that L stands for –L 1 -L 2 -L 3 -L 4 -L 5 -L 6 – L 1 , L 3 , L 5 Each independently represents a 4- to 12-membered heterocycloalkyl group, a 3- to 12-membered cycloalkyl group, -C(O)-, -N(R L )-、-C(O)N(R L )-、-N(R L )C(O)-, O or a bond, the heterocyclyl or cycloalkyl group may be optionally substituted by 0, 1, 2, 3 or 4 of the following substituents: halogen, hydroxy, amino, methyl or oxo (=O); L 2 , L 4 , L 6 Each independently represents -(OCH2CH2) m -、-(OCH2CH2CH2) m -、-(CH2) n -、-C(O)-、-N(R L )-、-C(O)N(R L )-、-N(R L )C(O)-, -C≡C-, O or a bond; R L Each independently represents H, C1-C3 alkyl; m represents 1, 2, 3, 4; n represents 1, 2, 3, 4, 5, 6; L may be optionally substituted with 0, 1, 2, 3 or 4 of the following substituents: fluoro, hydroxy, methyl or oxo (=0).
18. A compound according to any preceding claim, or a stereoisomer, tautomer, solvate, pharmaceutically acceptable salt, metabolite, isotopic derivative, N-oxide or prodrug thereof, characterized in that L 1 , L 3 , L 5 Each independently represents a 4- to 12-membered heterocycloalkyl group, a 3- to 12-membered cycloalkyl group, -C(O)-, -N(R L )-, O or a bond, the heterocyclyl or cycloalkyl may each be optionally substituted by 0, 1, 2, 3 or 4 of the following substituents: halogen, hydroxy, amino, methyl or oxo (=O); preferably, the heterocyclyl or cycloalkyl may each be optionally substituted by 0, 1, 2, 3 or 4 of the following substituents: halogen, methyl; more preferably, the heterocyclyl or cycloalkyl is substituted by 0 substituents.
19. A compound according to any preceding claim, or a stereoisomer, tautomer, solvate, pharmaceutically acceptable salt, metabolite, isotopic derivative, N-oxide or prodrug thereof, characterized in that L 2 , L 4 , L 6 Each independently represents -(OCH2CH2) m -、-(CH2) n -、-C(O)-、-N(R L )-, -C≡C-, O or a bond; preferably, L 2 , L 4 , L 6 Each independently represents -(CH2) n -、-C(O)-、-N(R L, )-, -C≡C-, O or a bond; m means 1 or 2; n represents 1, 2, 3, 4, 5 or 6.
20. A compound according to any preceding claim, or a stereoisomer, tautomer, solvate, pharmaceutically acceptable salt, metabolite, isotopic derivative, N-oxide or prodrug thereof, characterized in that L is selected from the following structures:
21. A compound having the structure shown below:
22. A pharmaceutical composition comprising a compound according to any one of claims 1 to 21, or a stereoisomer, tautomer, solvate, pharmaceutically acceptable salt, metabolite, isotopic derivative, N-oxide or prodrug thereof, and a pharmaceutically acceptable carrier, diluent or excipient.
23. Use of the compound according to any one of claims 1 to 21, or its stereoisomer, tautomer, solvate, pharmaceutically acceptable salt, metabolite, isotope derivative, N-oxide or prodrug, or the pharmaceutical composition according to claim 22 in the preparation of a medicament for preventing and / or treating a disease associated with HPK1 activity.
24. A method for preventing and / or treating a disease associated with HPK1 activity, comprising administering to a patient in need thereof a therapeutically effective amount of a compound according to any one of claims 1 to 21, or a stereoisomer, tautomer, solvate, pharmaceutically acceptable salt, metabolite, isotope derivative, N-oxide or prodrug thereof, or a pharmaceutical composition according to claim 22.
25. The use according to claim 23 or the method according to claim 24, wherein The HPK1 activity-related diseases include cancer or immune diseases; the cancer is preferably lung cancer, thyroid cancer, liver cancer, colorectal cancer, colon cancer, rectal cancer, pancreatic cancer, gastric cancer, esophageal cancer, squamous cell carcinoma, head and neck cancer, oral cancer, thyroid cancer, nasopharyngeal carcinoma, breast cancer, ovarian cancer, prostate cancer, cervical cancer, kidney cancer, endometrial cancer, bladder cancer, bone cancer, brain cancer, skin cancer, melanoma, sarcoma, cell tumor, glioma, blood tumor and lymphoma; the immune disease is preferably lupus erythematosus, psoriasis, inflammatory bowel disease and rheumatoid arthritis.
26. The use according to claim 23 or the method according to claim 24, wherein The compound according to any one of claims 1 to 21, or its stereoisomer, tautomer, solvate, pharmaceutically acceptable salt, metabolite, isotope derivative, N-oxide or prodrug, or the pharmaceutical composition according to claim 22 can be used alone or in combination with other types of pharmaceutical preparations and / or treatment methods.
Citation Information
Cited By
HPK1 targeting compounds and uses thereof
US20260144881A1
HPK1 degradation agent and use thereof in field of medicine
WO2025103489A1
HPK1 targeting compounds and uses thereof
WO2026072991A1
